Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">African Program for Onchocerciasis Control 1995–2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases</title><author><name sortKey="Krotneva, Stanimira P" sort="Krotneva, Stanimira P" uniqKey="Krotneva S" first="Stanimira P." last="Krotneva">Stanimira P. Krotneva</name><affiliation><nlm:aff id="aff001"><addr-line>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Coffeng, Luc E" sort="Coffeng, Luc E" uniqKey="Coffeng L" first="Luc E." last="Coffeng">Luc E. Coffeng</name><affiliation><nlm:aff id="aff001"><addr-line>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Noma, Mounkaila" sort="Noma, Mounkaila" uniqKey="Noma M" first="Mounkaila" last="Noma">Mounkaila Noma</name><affiliation><nlm:aff id="aff002"><addr-line>African Programme for Onchocerciasis Control, Ouagadougou, Burkina Faso</addr-line></nlm:aff></affiliation></author><author><name sortKey="Zoure, Honorat G M" sort="Zoure, Honorat G M" uniqKey="Zoure H" first="Honorat G. M." last="Zouré">Honorat G. M. Zouré</name><affiliation><nlm:aff id="aff002"><addr-line>African Programme for Onchocerciasis Control, Ouagadougou, Burkina Faso</addr-line></nlm:aff></affiliation></author><author><name sortKey="Bakone, Lalle" sort="Bakone, Lalle" uniqKey="Bakone L" first="Lalle" last="Bakoné">Lalle Bakoné</name><affiliation><nlm:aff id="aff002"><addr-line>African Programme for Onchocerciasis Control, Ouagadougou, Burkina Faso</addr-line></nlm:aff></affiliation></author><author><name sortKey="Amazigo, Uche V" sort="Amazigo, Uche V" uniqKey="Amazigo U" first="Uche V." last="Amazigo">Uche V. Amazigo</name><affiliation><nlm:aff id="aff003"><addr-line>Independent consultant, Enugu, Nigeria</addr-line></nlm:aff></affiliation></author><author><name sortKey="De Vlas, Sake J" sort="De Vlas, Sake J" uniqKey="De Vlas S" first="Sake J." last="De Vlas">Sake J. De Vlas</name><affiliation><nlm:aff id="aff001"><addr-line>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Stolk, Wilma A" sort="Stolk, Wilma A" uniqKey="Stolk W" first="Wilma A." last="Stolk">Wilma A. Stolk</name><affiliation><nlm:aff id="aff001"><addr-line>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26401658</idno><idno type="pmc">4581698</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581698</idno><idno type="RBID">PMC:4581698</idno><idno type="doi">10.1371/journal.pntd.0004051</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000401</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000401</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">African Program for Onchocerciasis Control 1995–2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases</title><author><name sortKey="Krotneva, Stanimira P" sort="Krotneva, Stanimira P" uniqKey="Krotneva S" first="Stanimira P." last="Krotneva">Stanimira P. Krotneva</name><affiliation><nlm:aff id="aff001"><addr-line>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Coffeng, Luc E" sort="Coffeng, Luc E" uniqKey="Coffeng L" first="Luc E." last="Coffeng">Luc E. Coffeng</name><affiliation><nlm:aff id="aff001"><addr-line>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Noma, Mounkaila" sort="Noma, Mounkaila" uniqKey="Noma M" first="Mounkaila" last="Noma">Mounkaila Noma</name><affiliation><nlm:aff id="aff002"><addr-line>African Programme for Onchocerciasis Control, Ouagadougou, Burkina Faso</addr-line></nlm:aff></affiliation></author><author><name sortKey="Zoure, Honorat G M" sort="Zoure, Honorat G M" uniqKey="Zoure H" first="Honorat G. M." last="Zouré">Honorat G. M. Zouré</name><affiliation><nlm:aff id="aff002"><addr-line>African Programme for Onchocerciasis Control, Ouagadougou, Burkina Faso</addr-line></nlm:aff></affiliation></author><author><name sortKey="Bakone, Lalle" sort="Bakone, Lalle" uniqKey="Bakone L" first="Lalle" last="Bakoné">Lalle Bakoné</name><affiliation><nlm:aff id="aff002"><addr-line>African Programme for Onchocerciasis Control, Ouagadougou, Burkina Faso</addr-line></nlm:aff></affiliation></author><author><name sortKey="Amazigo, Uche V" sort="Amazigo, Uche V" uniqKey="Amazigo U" first="Uche V." last="Amazigo">Uche V. Amazigo</name><affiliation><nlm:aff id="aff003"><addr-line>Independent consultant, Enugu, Nigeria</addr-line></nlm:aff></affiliation></author><author><name sortKey="De Vlas, Sake J" sort="De Vlas, Sake J" uniqKey="De Vlas S" first="Sake J." last="De Vlas">Sake J. De Vlas</name><affiliation><nlm:aff id="aff001"><addr-line>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands</addr-line></nlm:aff></affiliation></author><author><name sortKey="Stolk, Wilma A" sort="Stolk, Wilma A" uniqKey="Stolk W" first="Wilma A." last="Stolk">Wilma A. Stolk</name><affiliation><nlm:aff id="aff001"><addr-line>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">PLoS Neglected Tropical Diseases</title><idno type="ISSN">1935-2727</idno><idno type="eISSN">1935-2735</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Since its initiation in 1995, the African Program for Onchocerciasis Control (APOC) has had a substantial impact on the prevalence and burden of onchocerciasis through annual ivermectin mass treatment. Ivermectin is a broad-spectrum anti-parasitic agent that also has an impact on other co-endemic parasitic infections. In this study, we roughly assessed the additional impact of APOC activities on the burden of the most important off-target infections: soil-transmitted helminthiases (STH; ascariasis, trichuriasis, hookworm, and strongyloidiasis), lymphatic filariasis (LF), and scabies. Based on a literature review, we formulated assumptions about the impact of ivermectin treatment on the disease burden of these off-target infections. Using data on the number of ivermectin treatments in APOC regions and the latest estimates of the burden of disease, we then calculated the impact of APOC activities on off-target infections in terms of disability-adjusted life years (DALYs) averted. We conservatively estimated that between 1995 and 2010, annual ivermectin mass treatment has cumulatively averted about 500 thousand DALYs from co-endemic STH infections, LF, and scabies. This impact comprised approximately an additional 5.5% relative to the total burden averted from onchocerciasis (8.9 million DALYs) and indicates that the overall cost-effectiveness of APOC is even higher than previously reported.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Amazigo, U" uniqKey="Amazigo U">U Amazigo</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Coffeng, Le" uniqKey="Coffeng L">LE Coffeng</name></author><author><name sortKey="Stolk, Wa" uniqKey="Stolk W">WA Stolk</name></author><author><name sortKey="Zoure, Hgm" uniqKey="Zoure H">HGM Zouré</name></author><author><name sortKey="Veerman, Jl" uniqKey="Veerman J">JL Veerman</name></author><author><name sortKey="Agblewonu, Kb" uniqKey="Agblewonu K">KB Agblewonu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Coffeng, Le" uniqKey="Coffeng L">LE Coffeng</name></author><author><name sortKey="Stolk, Wa" uniqKey="Stolk W">WA Stolk</name></author><author><name sortKey="Zoure, Hgm" uniqKey="Zoure H">HGM Zouré</name></author><author><name sortKey="Veerman, Jl" uniqKey="Veerman J">JL Veerman</name></author><author><name sortKey="Agblewonu, Kb" uniqKey="Agblewonu K">KB Agblewonu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Campbell, Wc" uniqKey="Campbell W">WC Campbell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dourmishev, Al" uniqKey="Dourmishev A">AL Dourmishev</name></author><author><name sortKey="Dourmishev, La" uniqKey="Dourmishev L">LA Dourmishev</name></author><author><name sortKey="Schwartz, Ra" uniqKey="Schwartz R">RA Schwartz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bethony, J" uniqKey="Bethony J">J Bethony</name></author><author><name sortKey="Brooker, S" uniqKey="Brooker S">S Brooker</name></author><author><name sortKey="Albonico, M" uniqKey="Albonico M">M Albonico</name></author><author><name sortKey="Geiger, Sm" uniqKey="Geiger S">SM Geiger</name></author><author><name sortKey="Loukas, A" uniqKey="Loukas A">A Loukas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ottesen, Ea" uniqKey="Ottesen E">EA Ottesen</name></author><author><name sortKey="Hooper, Pj" uniqKey="Hooper P">PJ Hooper</name></author><author><name sortKey="Bradley, M" uniqKey="Bradley M">M Bradley</name></author><author><name sortKey="Biswas, G" uniqKey="Biswas G">G Biswas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Feldmeier, H" uniqKey="Feldmeier H">H Feldmeier</name></author><author><name sortKey="Heukelbach, J" uniqKey="Heukelbach J">J Heukelbach</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hotez, Pj" uniqKey="Hotez P">PJ Hotez</name></author><author><name sortKey="Kamath, A" uniqKey="Kamath A">A Kamath</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brooker, S" uniqKey="Brooker S">S Brooker</name></author><author><name sortKey="Hotez, Pj" uniqKey="Hotez P">PJ Hotez</name></author><author><name sortKey="Bundy, Dap" uniqKey="Bundy D">DAP Bundy</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Slater, H" uniqKey="Slater H">H Slater</name></author><author><name sortKey="Michael, E" uniqKey="Michael E">E Michael</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Murray, Cjl" uniqKey="Murray C">CJL Murray</name></author><author><name sortKey="Vos, T" uniqKey="Vos T">T Vos</name></author><author><name sortKey="Lozano, R" uniqKey="Lozano R">R Lozano</name></author><author><name sortKey="Naghavi, M" uniqKey="Naghavi M">M Naghavi</name></author><author><name sortKey="Flaxman, Ad" uniqKey="Flaxman A">AD Flaxman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hotez, Pj" uniqKey="Hotez P">PJ Hotez</name></author><author><name sortKey="Alvarado, M" uniqKey="Alvarado M">M Alvarado</name></author><author><name sortKey="Basa Ez, M G" uniqKey="Basa Ez M">M-G Basáñez</name></author><author><name sortKey="Bolliger, I" uniqKey="Bolliger I">I Bolliger</name></author><author><name sortKey="Bourne, R" uniqKey="Bourne R">R Bourne</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taticheff, S" uniqKey="Taticheff S">S Taticheff</name></author><author><name sortKey="Kebede, A" uniqKey="Kebede A">A Kebede</name></author><author><name sortKey="Bulto, T" uniqKey="Bulto T">T Bulto</name></author><author><name sortKey="Werkeneh, W" uniqKey="Werkeneh W">W Werkeneh</name></author><author><name sortKey="Tilahun, D" uniqKey="Tilahun D">D Tilahun</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tielsch, Jm" uniqKey="Tielsch J">JM Tielsch</name></author><author><name sortKey="Beeche, A" uniqKey="Beeche A">A Beeche</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Anosike, Jc" uniqKey="Anosike J">JC Anosike</name></author><author><name sortKey="Dozie, Ins" uniqKey="Dozie I">INS Dozie</name></author><author><name sortKey="Ameh, Gi" uniqKey="Ameh G">GI Ameh</name></author><author><name sortKey="Ukaga, Cn" uniqKey="Ukaga C">CN Ukaga</name></author><author><name sortKey="Nwoke, Beb" uniqKey="Nwoke B">BEB Nwoke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gutman, J" uniqKey="Gutman J">J Gutman</name></author><author><name sortKey="Emukah, E" uniqKey="Emukah E">E Emukah</name></author><author><name sortKey="Okpala, N" uniqKey="Okpala N">N Okpala</name></author><author><name sortKey="Okoro, C" uniqKey="Okoro C">C Okoro</name></author><author><name sortKey="Obasi, A" uniqKey="Obasi A">A Obasi</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Yelifari, L" uniqKey="Yelifari L">L Yelifari</name></author><author><name sortKey="Bloch, P" uniqKey="Bloch P">P Bloch</name></author><author><name sortKey="Magnussen, P" uniqKey="Magnussen P">P Magnussen</name></author><author><name sortKey="Van Lieshout, L" uniqKey="Van Lieshout L">L van Lieshout</name></author><author><name sortKey="Dery, G" uniqKey="Dery G">G Dery</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Medley, Gf" uniqKey="Medley G">GF Medley</name></author><author><name sortKey="Guyatt, Hl" uniqKey="Guyatt H">HL Guyatt</name></author><author><name sortKey="Bundy, Da" uniqKey="Bundy D">DA Bundy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, Ms" uniqKey="Chan M">MS Chan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bundy, Da" uniqKey="Bundy D">DA Bundy</name></author><author><name sortKey="De Silva, Nr" uniqKey="De Silva N">NR de Silva</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Noma, M" uniqKey="Noma M">M Noma</name></author><author><name sortKey="Nwoke, Beb" uniqKey="Nwoke B">BEB Nwoke</name></author><author><name sortKey="Nutall, I" uniqKey="Nutall I">I Nutall</name></author><author><name sortKey="Tambala, Pa" uniqKey="Tambala P">PA Tambala</name></author><author><name sortKey="Enyong, P" uniqKey="Enyong P">P Enyong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brooker, S" uniqKey="Brooker S">S Brooker</name></author><author><name sortKey="Hotez, Pj" uniqKey="Hotez P">PJ Hotez</name></author><author><name sortKey="Bundy, Dap" uniqKey="Bundy D">DAP Bundy</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Belizario, Vy" uniqKey="Belizario V">VY Belizario</name></author><author><name sortKey="Amarillo, Me" uniqKey="Amarillo M">ME Amarillo</name></author><author><name sortKey="De Leon, Wu" uniqKey="De Leon W">WU de Leon</name></author><author><name sortKey="De Los Reyes, Ae" uniqKey="De Los Reyes A">AE de los Reyes</name></author><author><name sortKey="Bugayong, Mg" uniqKey="Bugayong M">MG Bugayong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Freedman, Do" uniqKey="Freedman D">DO Freedman</name></author><author><name sortKey="Zierdt, Ws" uniqKey="Zierdt W">WS Zierdt</name></author><author><name sortKey="Lujan, A" uniqKey="Lujan A">A Lujan</name></author><author><name sortKey="Nutman, Tb" uniqKey="Nutman T">TB Nutman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Naquira, C" uniqKey="Naquira C">C Naquira</name></author><author><name sortKey="Jimenez, G" uniqKey="Jimenez G">G Jimenez</name></author><author><name sortKey="Guerra, Jg" uniqKey="Guerra J">JG Guerra</name></author><author><name sortKey="Bernal, R" uniqKey="Bernal R">R Bernal</name></author><author><name sortKey="Nalin, Dr" uniqKey="Nalin D">DR Nalin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wen, L Y" uniqKey="Wen L">L-Y Wen</name></author><author><name sortKey="Yan, X L" uniqKey="Yan X">X-L Yan</name></author><author><name sortKey="Sun, F H" uniqKey="Sun F">F-H Sun</name></author><author><name sortKey="Fang, Y Y" uniqKey="Fang Y">Y-Y Fang</name></author><author><name sortKey="Yang, M J" uniqKey="Yang M">M-J Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Richard Lenoble, D" uniqKey="Richard Lenoble D">D Richard-Lenoble</name></author><author><name sortKey="Kombila, M" uniqKey="Kombila M">M Kombila</name></author><author><name sortKey="Rupp, Ea" uniqKey="Rupp E">EA Rupp</name></author><author><name sortKey="Pappayliou, Es" uniqKey="Pappayliou E">ES Pappayliou</name></author><author><name sortKey="Gaxotte, P" uniqKey="Gaxotte P">P Gaxotte</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hotez, Pj" uniqKey="Hotez P">PJ Hotez</name></author><author><name sortKey="Molyneux, Dh" uniqKey="Molyneux D">DH Molyneux</name></author><author><name sortKey="Fenwick, A" uniqKey="Fenwick A">A Fenwick</name></author><author><name sortKey="Kumaresan, J" uniqKey="Kumaresan J">J Kumaresan</name></author><author><name sortKey="Sachs, Se" uniqKey="Sachs S">SE Sachs</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Silva, Nr" uniqKey="De Silva N">NR De Silva</name></author><author><name sortKey="Guyatt, Hl" uniqKey="Guyatt H">HL Guyatt</name></author><author><name sortKey="Bundy, Da" uniqKey="Bundy D">DA Bundy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Albonico, M" uniqKey="Albonico M">M Albonico</name></author><author><name sortKey="Allen, H" uniqKey="Allen H">H Allen</name></author><author><name sortKey="Chitsulo, L" uniqKey="Chitsulo L">L Chitsulo</name></author><author><name sortKey="Engels, D" uniqKey="Engels D">D Engels</name></author><author><name sortKey="Gabrielli, A F" uniqKey="Gabrielli A">A-F Gabrielli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moncayo, Al" uniqKey="Moncayo A">AL Moncayo</name></author><author><name sortKey="Vaca, M" uniqKey="Vaca M">M Vaca</name></author><author><name sortKey="Amorim, L" uniqKey="Amorim L">L Amorim</name></author><author><name sortKey="Rodriguez, A" uniqKey="Rodriguez A">A Rodriguez</name></author><author><name sortKey="Erazo, S" uniqKey="Erazo S">S Erazo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Whitworth, Ja" uniqKey="Whitworth J">JA Whitworth</name></author><author><name sortKey="Morgan, D" uniqKey="Morgan D">D Morgan</name></author><author><name sortKey="Maude, Gh" uniqKey="Maude G">GH Maude</name></author><author><name sortKey="Mcnicholas, Am" uniqKey="Mcnicholas A">AM McNicholas</name></author><author><name sortKey="Taylor, Dw" uniqKey="Taylor D">DW Taylor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Elkins, Db" uniqKey="Elkins D">DB Elkins</name></author><author><name sortKey="Haswell Elkins, M" uniqKey="Haswell Elkins M">M Haswell-Elkins</name></author><author><name sortKey="Anderson, Rm" uniqKey="Anderson R">RM Anderson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xia, Zh" uniqKey="Xia Z">ZH Xia</name></author><author><name sortKey="Su, Yl" uniqKey="Su Y">YL Su</name></author><author><name sortKey="Yao, Sy" uniqKey="Yao S">SY Yao</name></author><author><name sortKey="Shen, Br" uniqKey="Shen B">BR Shen</name></author><author><name sortKey="Wen, Ly" uniqKey="Wen L">LY Wen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shikiya, K" uniqKey="Shikiya K">K Shikiya</name></author><author><name sortKey="Uehara, T" uniqKey="Uehara T">T Uehara</name></author><author><name sortKey="Uechi, H" uniqKey="Uechi H">H Uechi</name></author><author><name sortKey="Ohshiro, J" uniqKey="Ohshiro J">J Ohshiro</name></author><author><name sortKey="Arakaki, T" uniqKey="Arakaki T">T Arakaki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shikiya, K" uniqKey="Shikiya K">K Shikiya</name></author><author><name sortKey="Kinjo, N" uniqKey="Kinjo N">N Kinjo</name></author><author><name sortKey="Uehara, T" uniqKey="Uehara T">T Uehara</name></author><author><name sortKey="Uechi, H" uniqKey="Uechi H">H Uechi</name></author><author><name sortKey="Ohshiro, J" uniqKey="Ohshiro J">J Ohshiro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Datry, A" uniqKey="Datry A">A Datry</name></author><author><name sortKey="Hilmarsdottir, I" uniqKey="Hilmarsdottir I">I Hilmarsdottir</name></author><author><name sortKey="Mayorga Sagastume, R" uniqKey="Mayorga Sagastume R">R Mayorga-Sagastume</name></author><author><name sortKey="Lyagoubi, M" uniqKey="Lyagoubi M">M Lyagoubi</name></author><author><name sortKey="Gaxotte, P" uniqKey="Gaxotte P">P Gaxotte</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marti, H" uniqKey="Marti H">H Marti</name></author><author><name sortKey="Haji, Hj" uniqKey="Haji H">HJ Haji</name></author><author><name sortKey="Savioli, L" uniqKey="Savioli L">L Savioli</name></author><author><name sortKey="Chwaya, Hm" uniqKey="Chwaya H">HM Chwaya</name></author><author><name sortKey="Mgeni, Af" uniqKey="Mgeni A">AF Mgeni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nontasut, P" uniqKey="Nontasut P">P Nontasut</name></author><author><name sortKey="Muennoo, C" uniqKey="Muennoo C">C Muennoo</name></author><author><name sortKey="Sa Nguankiat, S" uniqKey="Sa Nguankiat S">S Sa-nguankiat</name></author><author><name sortKey="Fongsri, S" uniqKey="Fongsri S">S Fongsri</name></author><author><name sortKey="Vichit, A" uniqKey="Vichit A">A Vichit</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Olsen, A" uniqKey="Olsen A">A Olsen</name></author><author><name sortKey="Van Lieshout, L" uniqKey="Van Lieshout L">L van Lieshout</name></author><author><name sortKey="Marti, H" uniqKey="Marti H">H Marti</name></author><author><name sortKey="Polderman, T" uniqKey="Polderman T">T Polderman</name></author><author><name sortKey="Polman, K" uniqKey="Polman K">K Polman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Santiago, M" uniqKey="Santiago M">M Santiago</name></author><author><name sortKey="Leitao, B" uniqKey="Leitao B">B Leitão</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stern, Ms" uniqKey="Stern M">MS Stern</name></author><author><name sortKey="Joshpe, G" uniqKey="Joshpe G">G Joshpe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Plaisier, Ap" uniqKey="Plaisier A">AP Plaisier</name></author><author><name sortKey="Cao, Wc" uniqKey="Cao W">WC Cao</name></author><author><name sortKey="Van Oortmarssen, Gj" uniqKey="Van Oortmarssen G">GJ van Oortmarssen</name></author><author><name sortKey="Habbema, Jd" uniqKey="Habbema J">JD Habbema</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dunyo, Sk" uniqKey="Dunyo S">SK Dunyo</name></author><author><name sortKey="Nkrumah, Fk" uniqKey="Nkrumah F">FK Nkrumah</name></author><author><name sortKey="Simonsen, Pe" uniqKey="Simonsen P">PE Simonsen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taylor, Mj" uniqKey="Taylor M">MJ Taylor</name></author><author><name sortKey="Hoerauf, A" uniqKey="Hoerauf A">A Hoerauf</name></author><author><name sortKey="Bockarie, M" uniqKey="Bockarie M">M Bockarie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Richards, Fo" uniqKey="Richards F">FO Richards</name></author><author><name sortKey="Eigege, A" uniqKey="Eigege A">A Eigege</name></author><author><name sortKey="Pam, D" uniqKey="Pam D">D Pam</name></author><author><name sortKey="Kal, A" uniqKey="Kal A">A Kal</name></author><author><name sortKey="Lenhart, A" uniqKey="Lenhart A">A Lenhart</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kar, Sk" uniqKey="Kar S">SK Kar</name></author><author><name sortKey="Mania, J" uniqKey="Mania J">J Mania</name></author><author><name sortKey="Patnaik, S" uniqKey="Patnaik S">S Patnaik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Usha, V" uniqKey="Usha V">V Usha</name></author><author><name sortKey="Gopalakrishnan, Nair T V" uniqKey="Gopalakrishnan N">Nair T V Gopalakrishnan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sule, Hm" uniqKey="Sule H">HM Sule</name></author><author><name sortKey="Thacher, Td" uniqKey="Thacher T">TD Thacher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Meinking, Tl" uniqKey="Meinking T">TL Meinking</name></author><author><name sortKey="Taplin, D" uniqKey="Taplin D">D Taplin</name></author><author><name sortKey="Hermida, Jl" uniqKey="Hermida J">JL Hermida</name></author><author><name sortKey="Pardo, R" uniqKey="Pardo R">R Pardo</name></author><author><name sortKey="Kerdel, Fa" uniqKey="Kerdel F">FA Kerdel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heukelbach, J" uniqKey="Heukelbach J">J Heukelbach</name></author><author><name sortKey="Winter, B" uniqKey="Winter B">B Winter</name></author><author><name sortKey="Wilcke, T" uniqKey="Wilcke T">T Wilcke</name></author><author><name sortKey="Muehlen, M" uniqKey="Muehlen M">M Muehlen</name></author><author><name sortKey="Albrecht, S" uniqKey="Albrecht S">S Albrecht</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abedin, S" uniqKey="Abedin S">S Abedin</name></author><author><name sortKey="Narang, M" uniqKey="Narang M">M Narang</name></author><author><name sortKey="Gandhi, V" uniqKey="Gandhi V">V Gandhi</name></author><author><name sortKey="Narang, S" uniqKey="Narang S">S Narang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Badiaga, S" uniqKey="Badiaga S">S Badiaga</name></author><author><name sortKey="Foucault, C" uniqKey="Foucault C">C Foucault</name></author><author><name sortKey="Rogier, C" uniqKey="Rogier C">C Rogier</name></author><author><name sortKey="Doudier, B" uniqKey="Doudier B">B Doudier</name></author><author><name sortKey="Rovery, C" uniqKey="Rovery C">C Rovery</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hengge, Ur" uniqKey="Hengge U">UR Hengge</name></author><author><name sortKey="Currie, Bj" uniqKey="Currie B">BJ Currie</name></author><author><name sortKey="J Ger, G" uniqKey="J Ger G">G Jäger</name></author><author><name sortKey="Lupi, O" uniqKey="Lupi O">O Lupi</name></author><author><name sortKey="Schwartz, Ra" uniqKey="Schwartz R">RA Schwartz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gilmore, Sj" uniqKey="Gilmore S">SJ Gilmore</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lawrence, G" uniqKey="Lawrence G">G Lawrence</name></author><author><name sortKey="Leafasia, J" uniqKey="Leafasia J">J Leafasia</name></author><author><name sortKey="Sheridan, J" uniqKey="Sheridan J">J Sheridan</name></author><author><name sortKey="Hills, S" uniqKey="Hills S">S Hills</name></author><author><name sortKey="Wate, J" uniqKey="Wate J">J Wate</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Feldmeier, H" uniqKey="Feldmeier H">H Feldmeier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cestari, Tf" uniqKey="Cestari T">TF Cestari</name></author><author><name sortKey="Pessato, S" uniqKey="Pessato S">S Pessato</name></author><author><name sortKey="Ramos E Silva, M" uniqKey="Ramos E Silva M">M Ramos-e-Silva</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chaccour, Cj" uniqKey="Chaccour C">CJ Chaccour</name></author><author><name sortKey="Kobylinski, Kc" uniqKey="Kobylinski K">KC Kobylinski</name></author><author><name sortKey="Bassat, Q" uniqKey="Bassat Q">Q Bassat</name></author><author><name sortKey="Bousema, T" uniqKey="Bousema T">T Bousema</name></author><author><name sortKey="Drakeley, C" uniqKey="Drakeley C">C Drakeley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boussinesq, M" uniqKey="Boussinesq M">M Boussinesq</name></author><author><name sortKey="Gardon, J" uniqKey="Gardon J">J Gardon</name></author><author><name sortKey="Gardon Wendel, N" uniqKey="Gardon Wendel N">N Gardon-Wendel</name></author><author><name sortKey="Chippaux, J P" uniqKey="Chippaux J">J-P Chippaux</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boussinesq, M" uniqKey="Boussinesq M">M Boussinesq</name></author><author><name sortKey="Kamgno, J" uniqKey="Kamgno J">J Kamgno</name></author><author><name sortKey="Pion, Sd" uniqKey="Pion S">SD Pion</name></author><author><name sortKey="Gardon, J" uniqKey="Gardon J">J Gardon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zoure, Hgm" uniqKey="Zoure H">HGM Zouré</name></author><author><name sortKey="Wanji, S" uniqKey="Wanji S">S Wanji</name></author><author><name sortKey="Noma, M" uniqKey="Noma M">M Noma</name></author><author><name sortKey="Amazigo, Uv" uniqKey="Amazigo U">UV Amazigo</name></author><author><name sortKey="Diggle, Pj" uniqKey="Diggle P">PJ Diggle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stolk, Wa" uniqKey="Stolk W">WA Stolk</name></author><author><name sortKey="De Vlas, Sj" uniqKey="De Vlas S">SJ de Vlas</name></author><author><name sortKey="Borsboom, Gjjm" uniqKey="Borsboom G">GJJM Borsboom</name></author><author><name sortKey="Habbema, Jdf" uniqKey="Habbema J">JDF Habbema</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Knopp, S" uniqKey="Knopp S">S Knopp</name></author><author><name sortKey="Mohammed, K A" uniqKey="Mohammed K">K a Mohammed</name></author><author><name sortKey="Speich, B" uniqKey="Speich B">B Speich</name></author><author><name sortKey="Hattendorf, J" uniqKey="Hattendorf J">J Hattendorf</name></author><author><name sortKey="Khamis, Is" uniqKey="Khamis I">IS Khamis</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><journal-title-group><journal-title>PLoS Neglected Tropical Diseases</journal-title></journal-title-group><issn pub-type="ppub">1935-2727</issn><issn pub-type="epub">1935-2735</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26401658</article-id><article-id pub-id-type="pmc">4581698</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0004051</article-id><article-id pub-id-type="publisher-id">PNTD-D-15-00673</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>African Program for Onchocerciasis Control 1995–2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases</article-title><alt-title alt-title-type="running-head">APOC 1995-2010: Impact on Off-Target Infectious Diseases</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Krotneva</surname><given-names>Stanimira P.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Coffeng</surname><given-names>Luc E.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Noma</surname><given-names>Mounkaila</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zouré</surname><given-names>Honorat G. M.</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bakoné</surname><given-names>Lalle</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Amazigo</surname><given-names>Uche V.</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Vlas</surname><given-names>Sake J.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>‡</sup></xref></contrib><contrib contrib-type="author"><name><surname>Stolk</surname><given-names>Wilma A.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>‡</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands</addr-line></aff><aff id="aff002"><label>2</label><addr-line>African Programme for Onchocerciasis Control, Ouagadougou, Burkina Faso</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Independent consultant, Enugu, Nigeria</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Steinmann</surname><given-names>Peter</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"></xref></contrib></contrib-group><aff id="edit1"><addr-line>Swiss Tropical and Public Health Institute, SWITZERLAND</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p>MN, HGMZ, LB, and UVA are or have been employees of the African Programme for Onchocerciasis Control (APOC), World Health Organization. The authors state that their employment has not caused any conflict of interest in any of the following: study design, data collection, data analysis, interpretation, or decision to publish. This does not alter our adherence to all PLOS policies on sharing data and materials.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: SPK LEC SJdV WAS. Analyzed the data: SPK LEC. Contributed reagents/materials/analysis tools: MN HGMZ LB UVA. Wrote the paper: SPK LEC MN HGMZ LB UVA SJdV WAS. Literature search: SPK.</p></fn><fn fn-type="other" id="econtrib001"><p>‡ These authors also contributed equally to this work.</p></fn><corresp id="cor001">* E-mail: <email>I.coffeng@erasmusmc.nl</email>.</corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2015</year></pub-date><volume>9</volume><issue>9</issue><elocation-id>e0004051</elocation-id><history><date date-type="received"><day>21</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2015</year></date></history><permissions><copyright-year>2015</copyright-year><copyright-holder>Krotneva et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pntd.0004051.pdf"></self-uri><abstract><p>Since its initiation in 1995, the African Program for Onchocerciasis Control (APOC) has had a substantial impact on the prevalence and burden of onchocerciasis through annual ivermectin mass treatment. Ivermectin is a broad-spectrum anti-parasitic agent that also has an impact on other co-endemic parasitic infections. In this study, we roughly assessed the additional impact of APOC activities on the burden of the most important off-target infections: soil-transmitted helminthiases (STH; ascariasis, trichuriasis, hookworm, and strongyloidiasis), lymphatic filariasis (LF), and scabies. Based on a literature review, we formulated assumptions about the impact of ivermectin treatment on the disease burden of these off-target infections. Using data on the number of ivermectin treatments in APOC regions and the latest estimates of the burden of disease, we then calculated the impact of APOC activities on off-target infections in terms of disability-adjusted life years (DALYs) averted. We conservatively estimated that between 1995 and 2010, annual ivermectin mass treatment has cumulatively averted about 500 thousand DALYs from co-endemic STH infections, LF, and scabies. This impact comprised approximately an additional 5.5% relative to the total burden averted from onchocerciasis (8.9 million DALYs) and indicates that the overall cost-effectiveness of APOC is even higher than previously reported.</p></abstract><abstract abstract-type="summary"><title>Author Summary</title><p>Onchocerciasis, or river blindness, is an infectious disease caused by the worm <italic>Onchocerca volvulus</italic>, which is transmitted between humans through the bites of blackflies and causes deforming skin disease, itch, and vision loss. The African Programme for Onchocerciasis Control (APOC) aims to control morbidity due to onchocerciasis by implementing mass drug administration (MDA) with ivermectin in endemic areas, targeting the whole population except for children under five and pregnant women. Aside from its effect on onchocerciasis, ivermectin also affects other parasitic infections such as lymphatic filariasis, intestinal worm infections, and scabies, which are all significantly co-endemic in areas covered by APOC. In this paper, the researchers roughly estimate the health impact of ivermectin MDA on off-target infections based on the number of dispensed treatments up to 2010, published estimates of the disease burden of off-target infections, and the expected effect of ivermectin treatment on the burden of these infections (based on literature review). This off-target health impact of APOC constitutes about 500 thousand years worth of healthy years of life (an additional 5.5% on top of the impact of APOC on the burden of onchocerciasis) and indicates that the cost-effectiveness of APOC is even higher than previously estimated.</p></abstract><funding-group><funding-statement>This study was funded by the World Health Organization/African Programme for Onchocerciasis Control (APOC/CEV/322/07). MN, HGMZ, LB, and UVA are or have been employees of the African Programme for Onchocerciasis Control (APOC), World Health Organization, and were involved in data collection and writing of the manuscript. These authors state that their employment has not caused any conflict of interest in any of the following: study design, data collection, data analysis, interpretation, or decision to publish.</funding-statement></funding-group><counts><fig-count count="1"></fig-count><table-count count="2"></table-count><page-count count="14"></page-count></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>The African Program for Onchocerciasis Control (APOC) is an international program aimed at controlling the disease burden of human onchocerciasis (river blindness) in sub-Saharan Africa (SSA), and elimination of infection where possible, using mass drug treatment (MDA) [<xref rid="pntd.0004051.ref001" ref-type="bibr">1</xref>,<xref rid="pntd.0004051.ref002" ref-type="bibr">2</xref>]. Since its launch in 1995, APOC and partnering beneficiary countries have scaled up their control activities geographically to at least cover all meso- and hyperendemic areas, averting 8.9 million disability-adjusted life years (DALYs) through 2010, and eventually aiming to treat over 90 million people annually in 16 African countries by 2015, protecting a population at risk of onchocerciasis of 118 million [<xref rid="pntd.0004051.ref003" ref-type="bibr">3</xref>,<xref rid="pntd.0004051.ref004" ref-type="bibr">4</xref>]. The drug used for mass treatment of onchocerciasis, ivermectin, is distributed and administered in a single dose of 150–200 μg/kg of body weight annually. Chronically ill people, pregnant (or lactating) women, and children under five are excluded from treatment with ivermectin [<xref rid="pntd.0004051.ref001" ref-type="bibr">1</xref>].</p><p>Ivermectin is known to be effective against various infectious diseases other than onchocerciasis, the most important being soil-transmitted helminth (STH) infections, lymphatic filariasis (LF), and epidermal parasitic skin diseases (EPSDs) such as scabies [<xref rid="pntd.0004051.ref005" ref-type="bibr">5</xref>–<xref rid="pntd.0004051.ref011" ref-type="bibr">11</xref>]. In APOC countries, the prevalence of STH infections in school-age children ranges between 20% and 50% [<xref rid="pntd.0004051.ref012" ref-type="bibr">12</xref>]. LF is endemic in all APOC countries with an estimated overall prevalence of 6–9% [<xref rid="pntd.0004051.ref010" ref-type="bibr">10</xref>], and local prevalences typically ranging between 0–40% [<xref rid="pntd.0004051.ref013" ref-type="bibr">13</xref>]. Despite the lack of comprehensive epidemiological data, it is known that EPSDs are prevalent across SSA and that the associated morbidity is significant in regions of high poverty [<xref rid="pntd.0004051.ref009" ref-type="bibr">9</xref>,<xref rid="pntd.0004051.ref014" ref-type="bibr">14</xref>,<xref rid="pntd.0004051.ref015" ref-type="bibr">15</xref>]. Together, these infections are responsible for a considerable burden of disease [<xref rid="pntd.0004051.ref014" ref-type="bibr">14</xref>,<xref rid="pntd.0004051.ref015" ref-type="bibr">15</xref>]. Therefore, annual mass treatment with ivermectin is expected to have an additional health impact by averting part of the burden related to these off-target infections [<xref rid="pntd.0004051.ref008" ref-type="bibr">8</xref>,<xref rid="pntd.0004051.ref016" ref-type="bibr">16</xref>–<xref rid="pntd.0004051.ref019" ref-type="bibr">19</xref>]. Although these additional beneficial effects of ivermectin are being used to sensitise communities to participate in MDA, up till now, the off-target health impact has not been quantified and its importance remains unknown.</p><p>In this study, we quantified the health impact of APOC activities through 2010 on the burden of STH (ascariasis, trichuriasis, hookworm, and strongyloidiasis), LF, and scabies. We reviewed the literature to retrieve field studies examining the effect of ivermectin treatment on off-target infections and formulated assumptions about the impact of ivermectin mass treatment on the associated burden of disease. Next, we retrieved estimates of the disease burden of candidate off-target diseases from the Global Burden of Disease (GBD) 2010 Study [<xref rid="pntd.0004051.ref014" ref-type="bibr">14</xref>]. By combining this information with data on the number of ivermectin treatments given through 2010 (recorded by APOC), we roughly estimated the number of DALYs due to off-target infections averted by APOC.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>Assumptions about effect of ivermectin on burden of off-target infections</title><p>We first performed a systematic PubMed search to determine efficacy of ivermectin mono-treatment against off-target infection, defined as the ability to provide a clinically measurable and preferably beneficial effect. We used the key term “ivermectin” in combination with any of the following: “efficacy”, “mass treatment”, “morbidity control”. Searches were made without time limitations. If available, meta-analysis studies evaluating the efficacy of ivermectin against a specific disease were used. If meta-analysis studies were not available, clinical studies reporting the efficacy of treatment were selected if: (1) the treatment regime concerned a single dose of about 150–200 μg/kg of body weight, and (2) the efficacy was evaluated up to one month for STH infections and up to a year for filarial infections and EPSDs. We considered a month to be the threshold duration of the immediate effect of ivermectin on STH infections. For LF and EPSDs, longer periods were considered due to a lack of studies evaluating the efficacy of ivermectin as soon as one month after administration. Only studies reporting their results in terms of the following criteria were considered: (1) percent of patients cured and/or percent egg reduction for STH infections, (2) percent microfilaria (mf) reduction (microfilaricidal efficacy) and/or the percent reduction in female fecundity (embryostatic efficacy) in LF, and (3) percent of patients cured for EPSDs. For some EPSDs, clinical studies describing single cases were considered due to the rareness of their incidence. If repeated doses were given, it was noted.</p><p>Based on the results of the literature review, we formulated assumptions about the effect of ivermectin mono-treatment on the burden of (untreated) off-target infections, in terms of reduction in DALYs lost (<xref rid="pntd.0004051.box001" ref-type="boxed-text">Box 1</xref>). Assumptions were formulated while considering the following factors: the direct effect of ivermectin treatment on infection levels in individuals, the clinical manifestations of each disease, the short and long term effects of mass treatment on incidence and prevalence of morbidity, and the patterns of post-treatment re-infection. The effect of ivermectin was expressed as parameter <italic>β</italic><sub><italic>x</italic></sub> (range 0–1), which represents the average reduction in the burden of disease <italic>x</italic> in DALYs lost over a period of six years achieved thanks to mass treatment with ivermectin. The six-year period was based on APOC data on population coverage of ivermectin mass treatment, which suggest that most of the population in APOC areas has been subject to at least six rounds of mass treatment between 1995 and 2010 [<xref rid="pntd.0004051.ref003" ref-type="bibr">3</xref>]. For infections such as STH and scabies, in which morbidity is highly correlated with intensity of infection (parasite load), and treatment only influences transmission to a small extent, we assumed that the impact of treatment is the same each year. For LF, repeated mass treatment rounds are expected to have an increasingly higher impact on the disease burden, through the effects of mass treatment on transmission and prevention of further exposure to infection that would lead to chronic disability (e.g. lymphedema). We assumed that for LF, parameter <italic>β</italic><sub><italic>x</italic></sub> represents the average health impact in all areas subject to varying periods of ivermectin mass treatment.</p><boxed-text id="pntd.0004051.box001" position="float" orientation="portrait"><sec id="sec004"><title>Box 1. Reasoning and Assumptions Regarding the Effectiveness of an Average Round of Mass Treatment (Parameter <italic>β</italic><sub><italic>x</italic></sub>)</title><sec id="sec005"><title>Ascariasis</title><p>A single dose of ivermectin is highly efficacious against <italic>Ascaris lumbricoides</italic>, reducing fecal egg counts by 94–100% [<xref rid="pntd.0004051.ref028" ref-type="bibr">28</xref>,<xref rid="pntd.0004051.ref029" ref-type="bibr">29</xref>], and clearing infection in 78–100% [<xref rid="pntd.0004051.ref028" ref-type="bibr">28</xref>–<xref rid="pntd.0004051.ref032" ref-type="bibr">32</xref>]. The clinical manifestations of ascariasis include: malnutrition, intestinal obstruction, growth and cognitive delays [<xref rid="pntd.0004051.ref015" ref-type="bibr">15</xref>,<xref rid="pntd.0004051.ref033" ref-type="bibr">33</xref>]. They are associated with high intensity of infection (worm burden) [<xref rid="pntd.0004051.ref034" ref-type="bibr">34</xref>]. The immediate post-treatment health benefits include: weight/height gain, increased fitness and physical activity [<xref rid="pntd.0004051.ref007" ref-type="bibr">7</xref>,<xref rid="pntd.0004051.ref035" ref-type="bibr">35</xref>]. The long-term health benefits of treatment include: prevention of intestinal obstruction, increased school attendance, learning abilities, and cognitive testing [<xref rid="pntd.0004051.ref007" ref-type="bibr">7</xref>,<xref rid="pntd.0004051.ref018" ref-type="bibr">18</xref>,<xref rid="pntd.0004051.ref035" ref-type="bibr">35</xref>,<xref rid="pntd.0004051.ref036" ref-type="bibr">36</xref>]. Field studies show that post-treatment reinfection does not bring the worm burden or prevalence back to pre-treatment levels in treated communities [<xref rid="pntd.0004051.ref019" ref-type="bibr">19</xref>,<xref rid="pntd.0004051.ref037" ref-type="bibr">37</xref>,<xref rid="pntd.0004051.ref038" ref-type="bibr">38</xref>]. Based on this information, we assume that an average round of mass treatment with ivermectin reduces the burden of ascariasis by 50% (<italic>β</italic><sub><italic>asc</italic></sub> = 0.5).</p></sec><sec id="sec006"><title>Trichuriasis</title><p>A single dose of ivermectin has medium to high efficacy against <italic>Trichuris trichiura</italic>, reducing fecal egg counts by 86–93% [<xref rid="pntd.0004051.ref029" ref-type="bibr">29</xref>,<xref rid="pntd.0004051.ref030" ref-type="bibr">30</xref>], and clearing infection in 35–67%[<xref rid="pntd.0004051.ref029" ref-type="bibr">29</xref>–<xref rid="pntd.0004051.ref031" ref-type="bibr">31</xref>]. The clinical manifestations of trichuriasis include: inflammatory bowel disease, growth and cognitive delays [<xref rid="pntd.0004051.ref015" ref-type="bibr">15</xref>,<xref rid="pntd.0004051.ref033" ref-type="bibr">33</xref>], which are associated with high intensity of infection (worm burden). The immediate post-treatment health benefits include: weight/height gain, increased fitness and physical activity [<xref rid="pntd.0004051.ref007" ref-type="bibr">7</xref>,<xref rid="pntd.0004051.ref035" ref-type="bibr">35</xref>]. The long-term health benefits of treatment include: prevention of inflammatory bowel disease, increased school attendance, learning abilities, and cognitive testing [<xref rid="pntd.0004051.ref007" ref-type="bibr">7</xref>,<xref rid="pntd.0004051.ref018" ref-type="bibr">18</xref>,<xref rid="pntd.0004051.ref035" ref-type="bibr">35</xref>,<xref rid="pntd.0004051.ref036" ref-type="bibr">36</xref>]. Field studies show that post-treatment reinfection does not bring the worm burden or prevalence back to pre-treatment levels in treated communities with high initial prevalence [<xref rid="pntd.0004051.ref019" ref-type="bibr">19</xref>,<xref rid="pntd.0004051.ref036" ref-type="bibr">36</xref>,<xref rid="pntd.0004051.ref037" ref-type="bibr">37</xref>]. Based on this information, we assume that an average round of mass treatment with ivermectin reduces the burden of trichuriasis by 50% (<italic>β</italic><sub><italic>trich</italic></sub> = 0.5).</p></sec><sec id="sec007"><title>Hookworm infections</title><p>A single dose of ivermectin has low efficacy against <italic>Ancylostoma duodenale</italic> and <italic>Necator americanus</italic>, reducing fecal egg counts by 52–80% [<xref rid="pntd.0004051.ref029" ref-type="bibr">29</xref>,<xref rid="pntd.0004051.ref031" ref-type="bibr">31</xref>], and clearing infection in 12–33% [<xref rid="pntd.0004051.ref029" ref-type="bibr">29</xref>,<xref rid="pntd.0004051.ref031" ref-type="bibr">31</xref>,<xref rid="pntd.0004051.ref039" ref-type="bibr">39</xref>]. The clinical manifestations of hookworm include: iron-deficiency anemia, malnutrition, growth and cognitive delays, and poor pregnancy outcomes [<xref rid="pntd.0004051.ref015" ref-type="bibr">15</xref>,<xref rid="pntd.0004051.ref033" ref-type="bibr">33</xref>]. They are associated with high intensity of infection (worm burden). A round of mass treatment has a small impact on the worm burden due to the low efficacy of the drug [<xref rid="pntd.0004051.ref037" ref-type="bibr">37</xref>]. The immediate post-treatment health benefits include: weight/height gain, increased fitness [<xref rid="pntd.0004051.ref007" ref-type="bibr">7</xref>,<xref rid="pntd.0004051.ref035" ref-type="bibr">35</xref>]. The long-term health benefits of treatment include: prevention of anemia, malnutrition, growth and cognitive delays. Field studies show that post-treatment reinfection brings the prevalence back to pre-treatment values [<xref rid="pntd.0004051.ref019" ref-type="bibr">19</xref>,<xref rid="pntd.0004051.ref036" ref-type="bibr">36</xref>]. Based on this information, we assume that an average round of mass treatment with ivermectin reduces the burden of hookworm infections by 20% (<italic>β</italic><sub><italic>hook</italic></sub> = 0.2).</p></sec><sec id="sec008"><title>Strongyloidiasis</title><p>A single dose of ivermectin is highly efficacious against <italic>Strongyloides stercoralis</italic>, reducing fecal larval counts by 94–100% [<xref rid="pntd.0004051.ref029" ref-type="bibr">29</xref>,<xref rid="pntd.0004051.ref030" ref-type="bibr">30</xref>], and clearing infection in 83–100% [<xref rid="pntd.0004051.ref016" ref-type="bibr">16</xref>,<xref rid="pntd.0004051.ref030" ref-type="bibr">30</xref>,<xref rid="pntd.0004051.ref040" ref-type="bibr">40</xref>–<xref rid="pntd.0004051.ref042" ref-type="bibr">42</xref>]. Ivermectin is considered to be the drug of choice for treating strongyloidiasis [<xref rid="pntd.0004051.ref042" ref-type="bibr">42</xref>–<xref rid="pntd.0004051.ref046" ref-type="bibr">46</xref>]. A round of mass treatment rapidly lowers the worm burden the population [<xref rid="pntd.0004051.ref030" ref-type="bibr">30</xref>,<xref rid="pntd.0004051.ref037" ref-type="bibr">37</xref>,<xref rid="pntd.0004051.ref041" ref-type="bibr">41</xref>,<xref rid="pntd.0004051.ref043" ref-type="bibr">43</xref>]. The clinical manifestations of strongyloidiasis include: abdominal pain and discomfort, diarrhea, weight loss, pruritus, and the potentially deadly dissemination (hyperinfection) [<xref rid="pntd.0004051.ref045" ref-type="bibr">45</xref>]. The immediate post-treatment health benefits include: prevention of abdominal pain and discomfort, prevention of diarrhea, weight gain [<xref rid="pntd.0004051.ref045" ref-type="bibr">45</xref>,<xref rid="pntd.0004051.ref046" ref-type="bibr">46</xref>]. The long-term health benefits of treatment include: prevention of potentially fatal dissemination of infection [<xref rid="pntd.0004051.ref046" ref-type="bibr">46</xref>]. Although <italic>S</italic>. <italic>stercoralis</italic> can persist in an untreated individual for years due to autoinfection [<xref rid="pntd.0004051.ref047" ref-type="bibr">47</xref>], once eradicated during treatment, an individual can only be re-infected from the environment. Since no follow up studies were found in the literature for <italic>S</italic>. <italic>stercoralis</italic> reinfection, we assume that the environmental reinfection rate would be similar to that of other STH infections. Based on this information, we assume that an average round of mass treatment with ivermectin reduces the morbidity due to strongyloidiasis by 50% (<italic>β</italic><sub><italic>strong</italic></sub> = 0.5).</p></sec><sec id="sec009"><title>Lymphatic filariasis (LF)</title><p>A single dose of ivermectin has high microfilaricidal (100%) and intermediate embryostatic (35%) efficacy against LF [<xref rid="pntd.0004051.ref048" ref-type="bibr">48</xref>]. Microfilariae start to reappear at three months post treatment and reaches approximately 11% of pre-treatment values at twelve months [<xref rid="pntd.0004051.ref049" ref-type="bibr">49</xref>]. The clinical manifestations of LF include: adenolymphangitis, lymphedema, and hydrocele. Existing morbidity is not cured or improved by clearing the microfilaria or even the complete and persistent clearance of infection. Yet, through their impact on transmission, repeated rounds of ivermectin mass treatment help to prevent the onset of new cases and possibly the progression of early clinical manifestations [<xref rid="pntd.0004051.ref050" ref-type="bibr">50</xref>]. Annual ivermectin mass treatment does not interrupt the transmission of LF [<xref rid="pntd.0004051.ref051" ref-type="bibr">51</xref>]. However, given population turnover and a reduced incidence (and possibly progression) of clinical manifestations, mass treatment indirectly decreases the prevalence of clinical symptoms of LF over time. Based on this information, we assume that an average round of mass treatment with ivermectin reduces the burden due to LF by 10% (<italic>β</italic><sub><italic>LF</italic></sub> = 0.1).</p></sec><sec id="sec010"><title>Epidermal parasitic skin diseases (EPSDs)</title><p>A single dose of ivermectin is highly efficacious against EPSDs [<xref rid="pntd.0004051.ref006" ref-type="bibr">6</xref>], causing an immediate lowering of the intensity of infestation. One dose of ivermectin suppresses scabies infection for up to three months [<xref rid="pntd.0004051.ref052" ref-type="bibr">52</xref>], and even clears infestation in 70–100% [<xref rid="pntd.0004051.ref053" ref-type="bibr">53</xref>–<xref rid="pntd.0004051.ref055" ref-type="bibr">55</xref>]. A round of mass treatment lowers the intensity of infestation rapidly [<xref rid="pntd.0004051.ref056" ref-type="bibr">56</xref>,<xref rid="pntd.0004051.ref057" ref-type="bibr">57</xref>]. The clinical manifestations of EPSDs include: pruritus (itching), and secondary streptococcal infections [<xref rid="pntd.0004051.ref009" ref-type="bibr">9</xref>]. The immediate post-treatment health benefits include: prevention of secondary infections, decreased physical and mental discomfort of severe pruritus, increased libido [<xref rid="pntd.0004051.ref018" ref-type="bibr">18</xref>,<xref rid="pntd.0004051.ref058" ref-type="bibr">58</xref>,<xref rid="pntd.0004051.ref059" ref-type="bibr">59</xref>]. The long-term health benefits of treatment include: prevention of streptococcal pyoderma which in turn predisposes to rheumatic fever, acute glomerulonephritis and their respective long-term sequelae: rheumatic heart disease and chronic renal insufficiency [<xref rid="pntd.0004051.ref009" ref-type="bibr">9</xref>,<xref rid="pntd.0004051.ref060" ref-type="bibr">60</xref>–<xref rid="pntd.0004051.ref063" ref-type="bibr">63</xref>]. Based on this information, we assume that an average round of mass treatment with ivermectin reduces the morbidity due to EPSDs by 50% (<italic>β</italic><sub><italic>oncho</italic></sub> = 0.5)</p></sec></sec></boxed-text></sec><sec id="sec011"><title>Data sources for estimates of disease burden</title><p>From the GBD 2010 study [<xref rid="pntd.0004051.ref014" ref-type="bibr">14</xref>], we derived country-specific estimates of the burden per capita (DALYs lost per 100,000 persons) for ascariasis, trichuriasis, hookworm, LF, and EPSDs (scabies only) in 1995, 2000, 2005, and 2010 (extracted from the online GBD data visualization tool [<xref rid="pntd.0004051.ref020" ref-type="bibr">20</xref>]). For the years in between, we assumed that the disease burden of these off-target infections followed a trend consistent with exponential interpolation of the available estimates. For some countries covered by APOC, the GBD 2010 study reports a decline in the burden of off-target diseases between 1995 and 2010. In the current study, we assume that this decline is not due to APOC or other control activities, at worst leading to an underestimation of the health impact of ivermectin mass treatment on off-target diseases (i.e. because the counterfactual burden without these activities would be even higher than reported by GBD 2010).</p><p>Though the group of EPSDs consists of several infections such as scabies, tungiasis (sand fleas), pediculosis (lice), and several other infections [<xref rid="pntd.0004051.ref009" ref-type="bibr">9</xref>], for the purpose of this study, we only considered scabies, as burden estimates have been made only for this particular infection so far. Further, the GBD 2010 study does not provide estimates for the burden of strongyloidiasis, an STH, even though its prevalence in SSA is probably considerable (although of unknown size). We assumed that the burden due to strongyloidiasis amounts to 1/5 of the total burden caused by the three major STH infections (ascariasis, trichuriasis, and hookworm). This assumption was based on the estimate that the prevalence of the three major STH infections in SSA ranges between 20–50% [<xref rid="pntd.0004051.ref012" ref-type="bibr">12</xref>], and a large cross-sectional study in rural Ghana which reported a prevalence of strongyloidiasis of 11.6% [<xref rid="pntd.0004051.ref021" ref-type="bibr">21</xref>]. These figures suggest that the prevalence and presumably the burden of strongyloidiasis may be up to five times lower than the prevalence and burden of the other three more common STH infections. Given the uncertainty regarding the assumption, we varied it in the sensitivity analysis (details below).</p></sec><sec id="sec012"><title>Calculation of disease burden averted</title><p>We calculated the disease burden averted, <italic>Ma</italic><sub><italic>iyx</italic></sub> (in DALYs), for each selected off-target infection <italic>x</italic> and summed it over the sixteen countries in which APOC has been active between 1995 and 2010 using the following formula, where <italic>i</italic> represents a specific APOC country and <italic>y</italic> represents the year of mass treatment:
<disp-formula id="pntd.0004051.e001"><alternatives><graphic xlink:href="pntd.0004051.e001.jpg" id="pntd.0004051.e001g" position="anchor" mimetype="image" orientation="portrait"></graphic><mml:math id="M1"><mml:msub><mml:mrow><mml:mi>M</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:munderover><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>16</mml:mn></mml:mrow></mml:munderover><mml:mrow><mml:mrow><mml:munderover><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mn>1995</mml:mn></mml:mrow><mml:mrow><mml:mn>2010</mml:mn></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mrow><mml:mi>M</mml:mi><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>y</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:munderover><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>16</mml:mn></mml:mrow></mml:munderover><mml:mrow><mml:mrow><mml:munderover><mml:mo stretchy="false">∑</mml:mo><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mn>1995</mml:mn></mml:mrow><mml:mrow><mml:mn>2010</mml:mn></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>h</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>M</mml:mi><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>M</mml:mi><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>c</mml:mi><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>y</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula></p><p>In this formula, <italic>M</italic><sub><italic>ixy</italic></sub> reflects the annual burden per capita due to infection <italic>x</italic> (as reported by the GBD 2010 study). This figure was adjusted to represent the burden per capita in population eligible for mass treatment with ivermectin in APOC areas by adjusting for over- or underrepresentation of the disease burden in children under five and pregnant or lactating women who are not eligible for ivermectin (<inline-formula id="pntd.0004051.e002"><alternatives><graphic xlink:href="pntd.0004051.e002.jpg" id="pntd.0004051.e002g" position="anchor" mimetype="image" orientation="portrait"></graphic><mml:math id="M2"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>M</mml:mi><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>M</mml:mi><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>c</mml:mi><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula> is the fraction <inline-formula id="pntd.0004051.e003"><alternatives><graphic xlink:href="pntd.0004051.e003.jpg" id="pntd.0004051.e003g" position="anchor" mimetype="image" orientation="portrait"></graphic><mml:math id="M3"><mml:mfrac><mml:mrow><mml:mtext>proportion of burden in ivermectin-eligible population</mml:mtext></mml:mrow><mml:mrow><mml:mtext>proportion of population eligible for ivermectin</mml:mtext></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula>, where <italic>pMc</italic><sub><italic>x</italic></sub> + <italic>pMw</italic><sub><italic>x</italic></sub> is the proportion of the disease burden in children under five, and <italic>pc</italic> + <italic>pw</italic> is the proportion of children under five and pregnant or lactating women in the population). We further adjusted for clustering of disease burden in APOC regions compared to other country regions (<italic>h</italic><sub><italic>ix</italic></sub>). The adjusted burden per capita (<inline-formula id="pntd.0004051.e004"><alternatives><graphic xlink:href="pntd.0004051.e004.jpg" id="pntd.0004051.e004g" position="anchor" mimetype="image" orientation="portrait"></graphic><mml:math id="M4"><mml:msub><mml:mrow><mml:mi>h</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>M</mml:mi><mml:msub><mml:mrow><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>M</mml:mi><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>c</mml:mi><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>w</mml:mi></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>x</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:math></alternatives></inline-formula>) was then multiplied by the number of treated individuals <italic>T</italic><sub><italic>iy</italic></sub> for any given year <italic>y</italic> (extracted from APOC records), yielding the potential disease burden in treated people. Assumptions about the values of aforementioned parameters can be found in <xref rid="pntd.0004051.t001" ref-type="table">Table 1</xref>, along with the associated literature references [<xref rid="pntd.0004051.ref003" ref-type="bibr">3</xref>,<xref rid="pntd.0004051.ref011" ref-type="bibr">11</xref>,<xref rid="pntd.0004051.ref012" ref-type="bibr">12</xref>,<xref rid="pntd.0004051.ref014" ref-type="bibr">14</xref>,<xref rid="pntd.0004051.ref020" ref-type="bibr">20</xref>,<xref rid="pntd.0004051.ref022" ref-type="bibr">22</xref>–<xref rid="pntd.0004051.ref027" ref-type="bibr">27</xref>]. The potential disease burden in treated people was multiplied with the infection-specific ivermectin efficacy <italic>β</italic><sub><italic>x</italic></sub>, yielding the estimated averted disease burden related to infection <italic>x</italic> in country <italic>i</italic> for year <italic>y</italic>. Results were then summed over years and countries, resulting in a total estimated number of DALYs averted (<italic>Ma</italic><sub><italic>x</italic></sub>), related to infection <italic>x</italic>.</p><table-wrap id="pntd.0004051.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0004051.t001</object-id><label>Table 1</label><caption><title>Description of parameters and their values.</title></caption><alternatives><graphic id="pntd.0004051.t001g" xlink:href="pntd.0004051.t001"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Description</th><th align="left" rowspan="1" colspan="1">Assumption or reference</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>M</italic><sub><italic>ixy</italic></sub></td><td align="left" rowspan="1" colspan="1">Estimated burden of disease <italic>x</italic> per capita in country <italic>i</italic> and year <italic>y</italic> (1995–2010)</td><td align="left" rowspan="1" colspan="1">Global Burden of Disease 2010 study [<xref rid="pntd.0004051.ref014" ref-type="bibr">14</xref>,<xref rid="pntd.0004051.ref020" ref-type="bibr">20</xref>].</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>T</italic><sub><italic>iy</italic></sub></td><td align="left" rowspan="1" colspan="1">Number of people treated in country <italic>i</italic> and year <italic>y</italic> (1995–2010)</td><td align="left" rowspan="1" colspan="1">Coverage data from APOC records that were also used in a recent evaluation of the health impact and cost of APOC activities [<xref rid="pntd.0004051.ref003" ref-type="bibr">3</xref>,<xref rid="pntd.0004051.ref004" ref-type="bibr">4</xref>].</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>h</italic><sub><italic>ix</italic></sub></td><td align="left" rowspan="1" colspan="1">Heterogeneity index for disease <italic>x</italic> in country <italic>i</italic></td><td align="left" rowspan="1" colspan="1">The spread of STH infections in APOC countries was assessed by visually comparing REMO maps with maps published by the Global Atlas of Helminth Infections [<xref rid="pntd.0004051.ref012" ref-type="bibr">12</xref>,<xref rid="pntd.0004051.ref025" ref-type="bibr">25</xref>]. <italic>h</italic> = 1.0, when STH infections are highly prevalent across the whole country and 1.5 when certain areas of high prevalence of STH infections overlap APOC regions. For LF, <italic>h</italic> = 1.0 for all countries. For all other infections, <italic>h</italic> = 1.5 for CAR, Chad and Nigeria (as APOC covers about half of the aforementioned countries, the hypothetical maximum value of <italic>h</italic> would be 2.0 for those countries). For all other countries, we assumed <italic>h</italic> equal to 1.0.</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>pc</italic> + <italic>pw</italic></td><td align="left" rowspan="1" colspan="1">Proportion of children below five years of age and pregnant women in the population</td><td align="left" rowspan="1" colspan="1">Assumed to be 0.2 for all countries, based on data from U.S. Census Bureau [<xref rid="pntd.0004051.ref027" ref-type="bibr">27</xref>].</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>pMc</italic><sub><italic>x</italic></sub> + <italic>pMw</italic><sub><italic>x</italic></sub></td><td align="left" rowspan="1" colspan="1">Proportion of disease burden in pregnant women and children under the age of five years</td><td align="left" rowspan="1" colspan="1"><italic>pMc</italic><sub><italic>x</italic></sub> + <italic>pMw</italic><sub><italic>x</italic></sub> = 0.2 if burden is evenly distributed over pregnant women, children under five, and the rest of the population. For ascariasis and trichuriasis, <italic>pMc</italic><sub><italic>x</italic></sub> + <italic>pMw</italic><sub><italic>x</italic></sub> = 0.1, since the burden in young children is considered substantial [<xref rid="pntd.0004051.ref023" ref-type="bibr">23</xref>,<xref rid="pntd.0004051.ref024" ref-type="bibr">24</xref>], though highest in those eligible for treatment (5–14 years) [<xref rid="pntd.0004051.ref014" ref-type="bibr">14</xref>]. For hookworm, <italic>pMc</italic><sub><italic>x</italic></sub> + <italic>pMw</italic><sub><italic>x</italic></sub> = 0.3, since the burden in pregnant women is considered to be substantial [<xref rid="pntd.0004051.ref022" ref-type="bibr">22</xref>,<xref rid="pntd.0004051.ref026" ref-type="bibr">26</xref>].</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>β</italic><sub><italic>x</italic></sub></td><td align="left" rowspan="1" colspan="1">The average annual reduction in DALYs due to infection <italic>x</italic> over six annual rounds of treatment</td><td align="left" rowspan="1" colspan="1">See <xref rid="pntd.0004051.box001" ref-type="boxed-text">Box 1</xref>.</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec013"><title>Sensitivity analysis</title><p>A univariate sensitivity analysis was performed to assess how the main result (number of DALYs averted related to off-target infections) changed when parameter <italic>β</italic><sub><italic>x</italic></sub> was increased or decreased by 20%. The value of 20% was chosen because larger increases or decreases of the effectiveness of ivermectin against off-target infections are highly unlikely to occur in field settings. Likewise, the assigned value of <italic>h</italic><sub><italic>ix</italic></sub> was varied by ±20% for those countries where <italic>h</italic><sub><italic>ix</italic></sub> was initially set to 1.5 (see <xref rid="pntd.0004051.t001" ref-type="table">Table 1</xref>). In addition, prevalence and burden of STH infections or EPSDs were assumed to either be overrepresented in APOC regions for all or none of the countries covered by APOC. The impact of the assumption regarding burden due to strongyloidiasis (1/5 of the total burden due to other STH infections) was examined by halving or doubling the assumed proportion. Finally, we also performed a multivariate sensitivity analysis by simultaneously increasing or decreasing all assumed <italic>β</italic><sub><italic>x</italic></sub> parameters by 20% as an extreme scenario.</p></sec></sec><sec sec-type="results" id="sec014"><title>Results</title><p>We assumed that each year, mass treatment would avert some fraction <italic>β</italic><sub><italic>x</italic></sub> of the potential disease burden in treated communities. Based on literature, this fraction was assumed to be 0.5 for ascariasis, trichuriasis, strongyloidiasis and EPSDs, 0.2 for hookworm infections, and 0.1 for LF (<xref rid="pntd.0004051.box001" ref-type="boxed-text">Box 1</xref>).</p><p>We estimated that without APOC (counterfactual situation assuming that there is no mass treatment with ivermectin by APOC), the potential disease burden of STH infections, lymphatic filariasis, and EPSD in individuals otherwise treated with ivermectin would amount to a cumulative burden of 1.7 million DALYs between 1995 and 2010. Of these, 493 thousand DALYs were averted by APOC through ivermectin mass treatment (<xref rid="pntd.0004051.t002" ref-type="table">Table 2</xref>). Most of the DALYs averted by APOC were related to ascariasis (162 thousand) and scabies (116 thousand), followed by LF (71 thousand), strongyloidiasis (67 thousand), and hookworm infection (61 thousand). Only a small part of the burden averted by APOC was related to trichuriasis (17 thousand). Nigeria contributed 53% of the total averted number of DALYs related to off-target infections (260 thousand of 493 thousand), followed by the DRC (62 thousand or 13%) and Cameroon (59 thousand or 12%).</p><table-wrap id="pntd.0004051.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0004051.t002</object-id><label>Table 2</label><caption><title>Burden of off-target infections averted by annual ivermectin mass treatment with ivermectin in Africa.</title><p>Figures represent the cumulative burden averted between 1995 and 2010 in areas covered by the African Programme for Onchocerciasis Control.</p></caption><alternatives><graphic id="pntd.0004051.t002g" xlink:href="pntd.0004051.t002"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"></th><th colspan="8" align="center" rowspan="1">Burden averted by ivermectin mass treatment (DALYs x 1,000)<xref rid="t002fn001" ref-type="table-fn"><sup>a</sup></xref></th></tr><tr><th align="left" rowspan="1" colspan="1">Country</th><th align="right" rowspan="1" colspan="1">Ascariasis</th><th align="right" rowspan="1" colspan="1">Trichur-iasis</th><th align="right" rowspan="1" colspan="1">Hook-worm</th><th align="right" rowspan="1" colspan="1">Strongy-loidiasis</th><th align="right" rowspan="1" colspan="1">Lymphatic filariasis</th><th align="right" rowspan="1" colspan="1">Scabies</th><th align="right" rowspan="1" colspan="1">Total</th><th align="right" rowspan="1" colspan="1">(%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Angola</td><td align="right" rowspan="1" colspan="1">0.2</td><td align="right" rowspan="1" colspan="1">0.1</td><td align="right" rowspan="1" colspan="1">0.2</td><td align="right" rowspan="1" colspan="1">0.1</td><td align="right" rowspan="1" colspan="1">0.2</td><td align="right" rowspan="1" colspan="1">0.2</td><td align="right" rowspan="1" colspan="1"><bold>0.9</bold></td><td align="right" rowspan="1" colspan="1">(0.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Burundi</td><td align="right" rowspan="1" colspan="1">0.4</td><td align="right" rowspan="1" colspan="1">0.1</td><td align="right" rowspan="1" colspan="1">1.3</td><td align="right" rowspan="1" colspan="1">0.7</td><td align="right" rowspan="1" colspan="1">0.8</td><td align="right" rowspan="1" colspan="1">1.2</td><td align="right" rowspan="1" colspan="1"><bold>4.6</bold></td><td align="right" rowspan="1" colspan="1">(0.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cameroon</td><td align="right" rowspan="1" colspan="1">23.6</td><td align="right" rowspan="1" colspan="1">6.1</td><td align="right" rowspan="1" colspan="1">5.7</td><td align="right" rowspan="1" colspan="1">7.2</td><td align="right" rowspan="1" colspan="1">8.5</td><td align="right" rowspan="1" colspan="1">8.0</td><td align="right" rowspan="1" colspan="1"><bold>59.3</bold></td><td align="right" rowspan="1" colspan="1">(12%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Central African Republic</td><td align="right" rowspan="1" colspan="1">0.5</td><td align="right" rowspan="1" colspan="1">0.2</td><td align="right" rowspan="1" colspan="1">4.3</td><td align="right" rowspan="1" colspan="1">0.3</td><td align="right" rowspan="1" colspan="1">2.6</td><td align="right" rowspan="1" colspan="1">3.0</td><td align="right" rowspan="1" colspan="1"><bold>10.9</bold></td><td align="right" rowspan="1" colspan="1">(2.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Chad</td><td align="right" rowspan="1" colspan="1">0.1</td><td align="right" rowspan="1" colspan="1">0.0</td><td align="right" rowspan="1" colspan="1">3.2</td><td align="right" rowspan="1" colspan="1">2.1</td><td align="right" rowspan="1" colspan="1">1.8</td><td align="right" rowspan="1" colspan="1">8.6</td><td align="right" rowspan="1" colspan="1"><bold>15.8</bold></td><td align="right" rowspan="1" colspan="1">(3.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Congo</td><td align="right" rowspan="1" colspan="1">1.5</td><td align="right" rowspan="1" colspan="1">0.8</td><td align="right" rowspan="1" colspan="1">0.6</td><td align="right" rowspan="1" colspan="1">0.5</td><td align="right" rowspan="1" colspan="1">0.8</td><td align="right" rowspan="1" colspan="1">0.8</td><td align="right" rowspan="1" colspan="1"><bold>5.1</bold></td><td align="right" rowspan="1" colspan="1">(1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Democratic Republic of Congo</td><td align="right" rowspan="1" colspan="1">18.1</td><td align="right" rowspan="1" colspan="1">5.5</td><td align="right" rowspan="1" colspan="1">11.9</td><td align="right" rowspan="1" colspan="1">1.6</td><td align="right" rowspan="1" colspan="1">11.0</td><td align="right" rowspan="1" colspan="1">14.0</td><td align="right" rowspan="1" colspan="1"><bold>62.0</bold></td><td align="right" rowspan="1" colspan="1">(12.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Equatorial Guinea</td><td align="right" rowspan="1" colspan="1">0.1</td><td align="right" rowspan="1" colspan="1">0.1</td><td align="right" rowspan="1" colspan="1">0.0</td><td align="right" rowspan="1" colspan="1">0.0</td><td align="right" rowspan="1" colspan="1">0.1</td><td align="right" rowspan="1" colspan="1">0.0</td><td align="right" rowspan="1" colspan="1"><bold>0.3</bold></td><td align="right" rowspan="1" colspan="1">(0.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ethiopia</td><td align="right" rowspan="1" colspan="1">2.6</td><td align="right" rowspan="1" colspan="1">1.7</td><td align="right" rowspan="1" colspan="1">2.5</td><td align="right" rowspan="1" colspan="1">0.1</td><td align="right" rowspan="1" colspan="1">2.2</td><td align="right" rowspan="1" colspan="1">8.0</td><td align="right" rowspan="1" colspan="1"><bold>17.2</bold></td><td align="right" rowspan="1" colspan="1">(3.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Liberia</td><td align="right" rowspan="1" colspan="1">1.1</td><td align="right" rowspan="1" colspan="1">0.5</td><td align="right" rowspan="1" colspan="1">3.0</td><td align="right" rowspan="1" colspan="1">3.7</td><td align="right" rowspan="1" colspan="1">2.0</td><td align="right" rowspan="1" colspan="1">2.9</td><td align="right" rowspan="1" colspan="1"><bold>13.2</bold></td><td align="right" rowspan="1" colspan="1">(2.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Malawi</td><td align="right" rowspan="1" colspan="1">0.3</td><td align="right" rowspan="1" colspan="1">0.0</td><td align="right" rowspan="1" colspan="1">0.7</td><td align="right" rowspan="1" colspan="1">2.6</td><td align="right" rowspan="1" colspan="1">0.4</td><td align="right" rowspan="1" colspan="1">5.3</td><td align="right" rowspan="1" colspan="1"><bold>9.2</bold></td><td align="right" rowspan="1" colspan="1">(1.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nigeria</td><td align="right" rowspan="1" colspan="1">112.0</td><td align="right" rowspan="1" colspan="1">1.2</td><td align="right" rowspan="1" colspan="1">20.5</td><td align="right" rowspan="1" colspan="1">45.3</td><td align="right" rowspan="1" colspan="1">31.8</td><td align="right" rowspan="1" colspan="1">49.1</td><td align="right" rowspan="1" colspan="1"><bold>259.9</bold></td><td align="right" rowspan="1" colspan="1">(52.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sudan and South Sudan<xref rid="t002fn002" ref-type="table-fn"><sup>b</sup></xref></td><td align="right" rowspan="1" colspan="1">0.1</td><td align="right" rowspan="1" colspan="1">0.0</td><td align="right" rowspan="1" colspan="1">0.9</td><td align="right" rowspan="1" colspan="1">1.9</td><td align="right" rowspan="1" colspan="1">0.6</td><td align="right" rowspan="1" colspan="1">5.5</td><td align="right" rowspan="1" colspan="1"><bold>9.0</bold></td><td align="right" rowspan="1" colspan="1">(1.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Uganda</td><td align="right" rowspan="1" colspan="1">0.6</td><td align="right" rowspan="1" colspan="1">0.2</td><td align="right" rowspan="1" colspan="1">3.3</td><td align="right" rowspan="1" colspan="1">3.4</td><td align="right" rowspan="1" colspan="1">2.0</td><td align="right" rowspan="1" colspan="1">4.2</td><td align="right" rowspan="1" colspan="1"><bold>13.8</bold></td><td align="right" rowspan="1" colspan="1">(2.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">United Republic of Tanzania</td><td align="right" rowspan="1" colspan="1">0.2</td><td align="right" rowspan="1" colspan="1">0.5</td><td align="right" rowspan="1" colspan="1">2.9</td><td align="right" rowspan="1" colspan="1">1.2</td><td align="right" rowspan="1" colspan="1">1.8</td><td align="right" rowspan="1" colspan="1">4.9</td><td align="right" rowspan="1" colspan="1"><bold>11.5</bold></td><td align="right" rowspan="1" colspan="1">(2.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="right" rowspan="1" colspan="1">161.5</td><td align="right" rowspan="1" colspan="1">16.9</td><td align="right" rowspan="1" colspan="1">61.0</td><td align="right" rowspan="1" colspan="1">70.9</td><td align="right" rowspan="1" colspan="1">66.6</td><td align="right" rowspan="1" colspan="1">115.7</td><td align="right" rowspan="1" colspan="1"><bold>492.5</bold></td><td align="right" rowspan="1" colspan="1">(100%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><sup>a</sup> These figures are the product of the potential disease burden due to off-target infections in people treated with ivermectin and the assumed effect of ivermectin treatment on the disease burden (see <xref rid="pntd.0004051.box001" ref-type="boxed-text">Box 1</xref>).</p></fn><fn id="t002fn002"><p><sup>b</sup> Estimates for Sudan and South Sudan are merged, as information on the burden per capita was reported for the two together [<xref rid="pntd.0004051.ref014" ref-type="bibr">14</xref>].</p></fn></table-wrap-foot></table-wrap><p><xref rid="pntd.0004051.g001" ref-type="fig">Fig 1</xref> shows the results of the sensitivity analyses. Changing individual <italic>β</italic><sub><italic>x</italic></sub> parameters by 20% resulted in estimates very similar to the main estimate. Obviously, increasing or decreasing all <italic>β</italic><sub><italic>x</italic></sub> parameters simultaneously by 20% resulted in ±20% deviations from the main estimate of 493 thousand DALYs averted. Assumed no clustering of STH and EPSDs in APOC areas (<italic>h</italic><sub><italic>ix</italic></sub> = 1.0) or clustering of all infections but LF in all countries (<italic>h</italic><sub><italic>ix</italic></sub> = 1.5) resulted in 16% lower and 19% higher estimates of total DALYs averted, respectively.</p><fig id="pntd.0004051.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0004051.g001</object-id><label>Fig 1</label><caption><title>Sensitivity analysis for the impact of assumed parameter values on the total averted burden.</title><p>For each parameter (y-axis), the figure between brackets indicates the relative amount by which it was varied in the sensitivity analysis.</p></caption><graphic xlink:href="pntd.0004051.g001"></graphic></fig></sec><sec sec-type="conclusions" id="sec015"><title>Discussion</title><p>The impact of APOC on off-target NTDs has previously been discussed and considered to be important, but difficult to quantify. We estimated that if APOC would not have been there, STH infections, strongyloidiasis, and scabies would have caused a cumulative burden of 1.7 million DALYs lost between 1995 and 2010 in individuals who would otherwise have been treated with ivermectin. We roughly estimated that of these 1.7 million DALYs, mass treatment with ivermectin has averted 500 thousand DALYs. This means that apart from the impact of APOC on the burden of onchocerciasis (8.9 million DALYs averted), there has been an additional 5.5% health impact through the effect of ivermectin mass treatment on off-target NTDs. This indicates that the cost-effectiveness of APOC is even somewhat higher than previously estimated.</p><p>The estimate of 500 thousand additionally averted DALYs was based on a simple approach that included assumptions about the impact of mass treatment on the burden of selected off-target infections endemic in APOC countries. Because we considered a period of six years for estimating the effects of ivermectin mass treatment (i.e. the minimum duration of most APOC programs), our approach may underestimate the averted burden in countries where ivermectin mass treatments have taken place for over six years (i.e. where effects on transmission may be larger). Also, we did not take into account the protective impact of ivermectin mass treatment due to a reduced transmission to children under five years of age and pregnant women (who receive no ivermectin). Gutman <italic>et al</italic>. show that the prevalence of some STH infections was significantly lower in pre-school children living in treated communities compared to pre-school children living in non-treated communities [<xref rid="pntd.0004051.ref019" ref-type="bibr">19</xref>]. Further, we assumed that APOC interventions have not been accounted for in the burden estimates for off-target NTDs provided by the GBD 2010 study, meaning that at worst (if GBD 2010 does account for APOC), ivermectin mass treatment has had a larger health impact than we estimate here. Also, ivermectin mass treatment probably has an effect on the burden of relatively rare or minor infections that were excluded from our analysis, such as enterobiasis, loiasis, streptocerciasis, serous cavity filariasis, and EPSDs other than scabies. Furthermore, ivermectin mass treatment also has a–yet to be quantified–effect on malaria transmission through the endectocidal effects of ivermectin on <italic>Anopheles</italic> vectors [<xref rid="pntd.0004051.ref064" ref-type="bibr">64</xref>]. On the other hand, we did not consider the burden of severe adverse effects of ivermectin treatment related to loiasis [<xref rid="pntd.0004051.ref065" ref-type="bibr">65</xref>,<xref rid="pntd.0004051.ref066" ref-type="bibr">66</xref>], which is endemic in parts of the APOC region [<xref rid="pntd.0004051.ref067" ref-type="bibr">67</xref>]. Overall, if anything, our results underestimate the true impact of APOC activities on off-target infections.</p><p>Our estimates of the impact of APOC on the burden of off-target diseases could be further refined with more sophisticated approaches, such as mathematical modeling. For some of the off-target infections, mathematical models have already been developed, such as for transmission and morbidity due ascariasis and transmission of lymphatic filariasis [<xref rid="pntd.0004051.ref022" ref-type="bibr">22</xref>,<xref rid="pntd.0004051.ref068" ref-type="bibr">68</xref>]. Epidemiological data and understanding of the mechanisms through which parasitic infections cause morbidity in the human host are needed to develop similar models for other parasitic infection, and update currently existing models. However, estimates made with such models are only usefully accurate if they are based on good information about the distribution of worms in host populations. Since such data are not yet widely available and the development of mathematical models is time-consuming and expensive, obtaining more precise estimates of the (averted) burden of off-target infections remains a challenge.</p><p>We ignored that in 16 countries, ivermectin mass treatment was planned to be combined with albendazole to target both onchocerciasis and LF from 2000 onwards [<xref rid="pntd.0004051.ref008" ref-type="bibr">8</xref>]. However, 11 countries had not provided any LF treatment by 2010 (Angola, Burundi, Chad, Congo, DRC, Equatorial Guinea, Liberia, Sudan, South Sudan), and two countries had only implemented 1–2 treatment rounds reaching <6% of the target population (Ethiopia and Central African Republic) [<xref rid="pntd.0004051.ref069" ref-type="bibr">69</xref>]. Only five countries (Cameroon, Malawi, Nigeria, Uganda, United Republic of Tanzania) had more mature LF elimination programmes that supplied 3–11 treatment rounds through 2010, reaching 25%–83% of the LF target population. We lack information on whether LF treatments took place in areas with LF only or co-endemic areas, but countries might have started in areas where mass treatment already took place for onchocerciasis. For these countries (especially Nigeria where many people live in co-endemic areas) it is therefore perhaps not justified to fully attribute the estimated effects on off-target diseases to APOC alone. It would be more useful to estimate the overall effect of repeated mass treatments on all target and off-target diseases; such estimates would be larger than the figures presented here, thanks to the addition of albendazole.</p><p>The so-called neglected tropical diseases (consisting of STH, filariases, EPSDs, and several other infections) are the most common conditions affecting the poorest 500 million people living in SSA [<xref rid="pntd.0004051.ref010" ref-type="bibr">10</xref>,<xref rid="pntd.0004051.ref015" ref-type="bibr">15</xref>]. The infections covered in our analysis have been estimated to be responsible for a burden of 8.3 million DALYs lost in SSA in 2010 [<xref rid="pntd.0004051.ref014" ref-type="bibr">14</xref>]. Compared to this, our estimate of the health impact of ivermectin mass treatment on off-target diseases is modest (493 thousand DALYs averted). In order to enhance the impact of mass treatment on LF and STH infections, it would be interesting to consider adding albendazole or other STH-specific drugs to mass treatments (targeting the appropriate age-groups). For instance, in a counterfactual scenario where APOC would have added albendazole to their community-directed treatment strategy from 2000 onwards, an additional 389 thousand DALYs would have been averted by 2010, assuming that MDA would have had a higher impact on ascariasis, trichuriasis, hookworm, and LF (i.e. <italic>β</italic><sub><italic>STH</italic></sub> = 0.9, instead of 0.5; <italic>β</italic><sub><italic>LF</italic></sub> = 0.3, instead of 0.1). Guidelines for what anthelminthic drugs should be used in different areas have already been formulated [<xref rid="pntd.0004051.ref070" ref-type="bibr">70</xref>]. Further, to sustain the off-target health impact after onchocerciasis and LF have been eliminated from APOC target areas, it should be considered to continue mass treatments against STH with albendazole (possibly combined with ivermectin against trichuriasis [<xref rid="pntd.0004051.ref071" ref-type="bibr">71</xref>]), either school-based (mainly covering the burden of ascariasis and trichuriasis in children) or community-based (covering the burden of all STH). This would also be in line with the London Declaration on Neglected Tropical Diseases [<xref rid="pntd.0004051.ref072" ref-type="bibr">72</xref>,<xref rid="pntd.0004051.ref073" ref-type="bibr">73</xref>].</p><p>In conclusion, we roughly estimated that ivermectin mass treatment coordinated by APOC has averted about 500 thousand DALYs related to off-target infections. This health impact constitutes an additional 5.5% on top of the impact of APOC on the burden of onchocerciasis, and indicates that the cost-effectiveness of APOC is even higher than previously estimated. To amplify and sustain this additional health impact, control programs could consider adding albendazole to mass treatments, and continue this after elimination of onchocerciasis and lymphatic filariasis.</p></sec><sec sec-type="supplementary-material" id="sec016"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pntd.0004051.s001"><label>S1 File</label><caption><title>Calculations and input data.</title><p>Excel spreadsheet.</p><p>(XLS)</p></caption><media xlink:href="pntd.0004051.s001.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pntd.0004051.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Amazigo</surname><given-names>U</given-names></name> (<year>2008</year>) <article-title>The African Programme for Onchocerciasis Control (APOC)</article-title>. <source>Ann Trop Med Parasitol</source><volume>102</volume> Suppl: <fpage>19</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">18718149</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref002"><label>2</label><mixed-citation publication-type="other">African Programme for Onchocerciasis Control (2010) Conceptual and operational framework of onchocerciasis elimination with ivermectin treatment. Ouagadougou.</mixed-citation></ref><ref id="pntd.0004051.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Coffeng</surname><given-names>LE</given-names></name>, <name><surname>Stolk</surname><given-names>WA</given-names></name>, <name><surname>Zouré</surname><given-names>HGM</given-names></name>, <name><surname>Veerman</surname><given-names>JL</given-names></name>, <name><surname>Agblewonu</surname><given-names>KB</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>African Programme for Onchocerciasis Control 1995–2015: model-estimated health impact and cost</article-title>. <source>PLoS Negl Trop Dis</source><volume>7</volume>: <fpage>e2032</fpage>.<pub-id pub-id-type="pmid">23383355</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Coffeng</surname><given-names>LE</given-names></name>, <name><surname>Stolk</surname><given-names>WA</given-names></name>, <name><surname>Zouré</surname><given-names>HGM</given-names></name>, <name><surname>Veerman</surname><given-names>JL</given-names></name>, <name><surname>Agblewonu</surname><given-names>KB</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>African Programme for Onchocerciasis Control 1995–2015: updated health impact estimates based on new disability weights</article-title>. <source>PLoS Negl Trop Dis</source><volume>8</volume>: <fpage>e2759</fpage>.<pub-id pub-id-type="pmid">24901642</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Campbell</surname><given-names>WC</given-names></name> (<year>1991</year>) <article-title>Ivermectin as an antiparasitic agent for use in humans</article-title>. <source>Ann Rev Microbiol</source><volume>45</volume>: <fpage>445</fpage>–<lpage>474</lpage>.<pub-id pub-id-type="pmid">1741621</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Dourmishev</surname><given-names>AL</given-names></name>, <name><surname>Dourmishev</surname><given-names>LA</given-names></name>, <name><surname>Schwartz</surname><given-names>RA</given-names></name> (<year>2005</year>) <article-title>Ivermectin: pharmacology and application in dermatology</article-title>. <source>Int J Dermatol</source><volume>44</volume>: <fpage>981</fpage>–<lpage>988</lpage>.<pub-id pub-id-type="pmid">16409259</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Bethony</surname><given-names>J</given-names></name>, <name><surname>Brooker</surname><given-names>S</given-names></name>, <name><surname>Albonico</surname><given-names>M</given-names></name>, <name><surname>Geiger</surname><given-names>SM</given-names></name>, <name><surname>Loukas</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm</article-title>. <source>Lancet</source><volume>367</volume>: <fpage>1521</fpage>–<lpage>1532</lpage>.<pub-id pub-id-type="pmid">16679166</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Ottesen</surname><given-names>EA</given-names></name>, <name><surname>Hooper</surname><given-names>PJ</given-names></name>, <name><surname>Bradley</surname><given-names>M</given-names></name>, <name><surname>Biswas</surname><given-names>G</given-names></name> (<year>2008</year>) <article-title>The global programme to eliminate lymphatic filariasis: health impact after 8 years</article-title>. <source>PLoS Negl Trop Dis</source><volume>2</volume>: <fpage>e317</fpage>.<pub-id pub-id-type="pmid">18841205</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Feldmeier</surname><given-names>H</given-names></name>, <name><surname>Heukelbach</surname><given-names>J</given-names></name> (<year>2009</year>) <article-title>Epidermal parasitic skin diseases: a neglected category of poverty-associated plagues</article-title>. <source>Bull World Heal Organ</source><volume>87</volume>: <fpage>152</fpage>–<lpage>159</lpage>.</mixed-citation></ref><ref id="pntd.0004051.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Hotez</surname><given-names>PJ</given-names></name>, <name><surname>Kamath</surname><given-names>A</given-names></name> (<year>2009</year>) <article-title>Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden</article-title>. <source>PLoS Negl Trop Dis</source><volume>3</volume>: <fpage>e412</fpage>.<pub-id pub-id-type="pmid">19707588</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Brooker</surname><given-names>S</given-names></name>, <name><surname>Hotez</surname><given-names>PJ</given-names></name>, <name><surname>Bundy</surname><given-names>DAP</given-names></name> (<year>2010</year>) <article-title>The global atlas of helminth infection: mapping the way forward in neglected tropical disease control</article-title>. <source>PLoS Negl Trop Dis</source><volume>4</volume>: <fpage>e779</fpage>.<pub-id pub-id-type="pmid">20668545</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref012"><label>12</label><mixed-citation publication-type="other">London School of Hygiene and Tropical Medicine. Global Atlas of Helminth Infections. <ext-link ext-link-type="uri" xlink:href="http://www.thiswormyworld.org">www.thiswormyworld.org</ext-link> (Accessed March 30, 2013).</mixed-citation></ref><ref id="pntd.0004051.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Slater</surname><given-names>H</given-names></name>, <name><surname>Michael</surname><given-names>E</given-names></name> (<year>2013</year>) <article-title>Mapping, Bayesian Geostatistical Analysis and Spatial Prediction of Lymphatic Filariasis Prevalence in Africa</article-title>. <source>PLoS One</source><volume>8</volume>: <fpage>e71574</fpage>.<pub-id pub-id-type="pmid">23951194</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Murray</surname><given-names>CJL</given-names></name>, <name><surname>Vos</surname><given-names>T</given-names></name>, <name><surname>Lozano</surname><given-names>R</given-names></name>, <name><surname>Naghavi</surname><given-names>M</given-names></name>, <name><surname>Flaxman</surname><given-names>AD</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title>. <source>Lancet</source><volume>380</volume>: <fpage>2197</fpage>–<lpage>2223</lpage>.<pub-id pub-id-type="pmid">23245608</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Hotez</surname><given-names>PJ</given-names></name>, <name><surname>Alvarado</surname><given-names>M</given-names></name>, <name><surname>Basáñez</surname><given-names>M-G</given-names></name>, <name><surname>Bolliger</surname><given-names>I</given-names></name>, <name><surname>Bourne</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>The Global Burden of Disease Study 2010: interpretation and implications for the neglected tropical diseases</article-title>. <source>PLoS Negl Trop Dis</source><volume>8</volume>: <fpage>e2865</fpage>.<pub-id pub-id-type="pmid">25058013</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Taticheff</surname><given-names>S</given-names></name>, <name><surname>Kebede</surname><given-names>A</given-names></name>, <name><surname>Bulto</surname><given-names>T</given-names></name>, <name><surname>Werkeneh</surname><given-names>W</given-names></name>, <name><surname>Tilahun</surname><given-names>D</given-names></name> (<year>1994</year>) <article-title>Effect of ivermectin (Mectizan) on intestinal nematodes</article-title>. <source>Ethiop Med J</source><volume>32</volume>: <fpage>7</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">8187782</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Tielsch</surname><given-names>JM</given-names></name>, <name><surname>Beeche</surname><given-names>A</given-names></name> (<year>2004</year>) <article-title>Impact of ivermectin on illness and disability associated with onchocerciasis</article-title>. <source>Trop Med Int Heal</source><volume>9</volume>: <fpage>A45</fpage>–<lpage>A56</lpage>.</mixed-citation></ref><ref id="pntd.0004051.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Anosike</surname><given-names>JC</given-names></name>, <name><surname>Dozie</surname><given-names>INS</given-names></name>, <name><surname>Ameh</surname><given-names>GI</given-names></name>, <name><surname>Ukaga</surname><given-names>CN</given-names></name>, <name><surname>Nwoke</surname><given-names>BEB</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>The varied beneficial effects of ivermectin (Mectizan) treatment, as observed within onchocerciasis foci in south-eastern Nigeria</article-title>. <source>Ann Trop Med Parasitol</source><volume>101</volume>: <fpage>593</fpage>–<lpage>600</lpage>.<pub-id pub-id-type="pmid">17877878</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Gutman</surname><given-names>J</given-names></name>, <name><surname>Emukah</surname><given-names>E</given-names></name>, <name><surname>Okpala</surname><given-names>N</given-names></name>, <name><surname>Okoro</surname><given-names>C</given-names></name>, <name><surname>Obasi</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Effects of annual mass treatment with ivermectin for onchocerciasis on the prevalence of intestinal helminths</article-title>. <source>Am J Trop Med Hyg</source><volume>83</volume>: <fpage>534</fpage>–<lpage>541</lpage>.<pub-id pub-id-type="pmid">20810817</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref020"><label>20</label><mixed-citation publication-type="other">Global Burden of Disease Study 2010 visualisation tool. <ext-link ext-link-type="uri" xlink:href="http://www.healthdata.org/data-visualization/gbd-cause-patterns">http://www.healthdata.org/data-visualization/gbd-cause-patterns</ext-link> (Accessed March 30, 2013).</mixed-citation></ref><ref id="pntd.0004051.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Yelifari</surname><given-names>L</given-names></name>, <name><surname>Bloch</surname><given-names>P</given-names></name>, <name><surname>Magnussen</surname><given-names>P</given-names></name>, <name><surname>van Lieshout</surname><given-names>L</given-names></name>, <name><surname>Dery</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Distribution of human Oesophagostomum bifurcum, hookworm and Strongyloides stercoralis infections in northern Ghana</article-title>. <source>Trans R Soc Trop Med Hyg</source><volume>99</volume>: <fpage>32</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="pmid">15550259</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Medley</surname><given-names>GF</given-names></name>, <name><surname>Guyatt</surname><given-names>HL</given-names></name>, <name><surname>Bundy</surname><given-names>DA</given-names></name> (<year>1993</year>) <article-title>A quantitative framework for evaluating the effect of community treatment on the morbidity due to ascariasis</article-title>. <source>Parasitology</source><volume>106</volume> (<issue>Pt 2</issue>: <fpage>211</fpage>–<lpage>221</lpage>.<pub-id pub-id-type="pmid">8446474</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Chan</surname><given-names>MS</given-names></name> (<year>1997</year>) <article-title>The global burden of intestinal nematode infections—fifty years on</article-title>. <source>Parasitol Today</source><volume>13</volume>: <fpage>438</fpage>–<lpage>443</lpage>.<pub-id pub-id-type="pmid">15275146</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Bundy</surname><given-names>DA</given-names></name>, <name><surname>de Silva</surname><given-names>NR</given-names></name> (<year>1998</year>) <article-title>Can we deworm this wormy world?</article-title><source>Br Med Bull</source><volume>54</volume>: <fpage>421</fpage>–<lpage>432</lpage>.<pub-id pub-id-type="pmid">9830207</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Noma</surname><given-names>M</given-names></name>, <name><surname>Nwoke</surname><given-names>BEB</given-names></name>, <name><surname>Nutall</surname><given-names>I</given-names></name>, <name><surname>Tambala</surname><given-names>PA</given-names></name>, <name><surname>Enyong</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Rapid epidemiological mapping of onchocerciasis (REMO): its application by the African Programme for Onchocerciasis Control (APOC)</article-title>. <source>Ann Trop Med Parasitol</source><volume>96</volume><issue>Suppl 1</issue>: <fpage>S29</fpage>–<lpage>S39</lpage>.<pub-id pub-id-type="pmid">12081248</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Brooker</surname><given-names>S</given-names></name>, <name><surname>Hotez</surname><given-names>PJ</given-names></name>, <name><surname>Bundy</surname><given-names>DAP</given-names></name> (<year>2008</year>) <article-title>Hookworm-related anaemia among pregnant women: a systematic review</article-title>. <source>PLoS Negl Trop Dis</source><volume>2</volume>: <fpage>e291</fpage>.<pub-id pub-id-type="pmid">18820740</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref027"><label>27</label><mixed-citation publication-type="other">U.S. Census Bureau. International database (IDB). <ext-link ext-link-type="uri" xlink:href="http://www.census.gov">www.census.gov</ext-link> (Accessed March 30, 2013).</mixed-citation></ref><ref id="pntd.0004051.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Belizario</surname><given-names>VY</given-names></name>, <name><surname>Amarillo</surname><given-names>ME</given-names></name>, <name><surname>de Leon</surname><given-names>WU</given-names></name>, <name><surname>de los Reyes</surname><given-names>AE</given-names></name>, <name><surname>Bugayong</surname><given-names>MG</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp</article-title>. <source>Bull World Heal Organ</source><volume>81</volume>: <fpage>35</fpage>–<lpage>42</lpage>.</mixed-citation></ref><ref id="pntd.0004051.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Freedman</surname><given-names>DO</given-names></name>, <name><surname>Zierdt</surname><given-names>WS</given-names></name>, <name><surname>Lujan</surname><given-names>A</given-names></name>, <name><surname>Nutman</surname><given-names>TB</given-names></name> (<year>1989</year>) <article-title>The efficacy of ivermectin in the chemotherapy of gastrointestinal helminthiasis in humans</article-title>. <source>J Infect Dis</source><volume>159</volume>: <fpage>1151</fpage>–<lpage>1153</lpage>.<pub-id pub-id-type="pmid">2723457</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Naquira</surname><given-names>C</given-names></name>, <name><surname>Jimenez</surname><given-names>G</given-names></name>, <name><surname>Guerra</surname><given-names>JG</given-names></name>, <name><surname>Bernal</surname><given-names>R</given-names></name>, <name><surname>Nalin</surname><given-names>DR</given-names></name>, <etal>et al</etal> (<year>1989</year>) <article-title>Ivermectin for human strongyloidiasis and other intestinal helminths</article-title>. <source>Am J Trop Med Hyg</source><volume>40</volume>: <fpage>304</fpage>–<lpage>309</lpage>.<pub-id pub-id-type="pmid">2929853</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Wen</surname><given-names>L-Y</given-names></name>, <name><surname>Yan</surname><given-names>X-L</given-names></name>, <name><surname>Sun</surname><given-names>F-H</given-names></name>, <name><surname>Fang</surname><given-names>Y-Y</given-names></name>, <name><surname>Yang</surname><given-names>M-J</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>A randomized, double-blind, multicenter clinical trial on the efficacy of ivermectin against intestinal nematode infections in China</article-title>. <source>Acta Trop</source><volume>106</volume>: <fpage>190</fpage>–<lpage>194</lpage>.<pub-id pub-id-type="pmid">18452885</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Richard-Lenoble</surname><given-names>D</given-names></name>, <name><surname>Kombila</surname><given-names>M</given-names></name>, <name><surname>Rupp</surname><given-names>EA</given-names></name>, <name><surname>Pappayliou</surname><given-names>ES</given-names></name>, <name><surname>Gaxotte</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>1988</year>) <article-title>Ivermectin in loiasis and concomitant O. volvulus and M. perstans infections</article-title>. <source>Am J Trop Med Hyg</source><volume>39</volume>: <fpage>480</fpage>–<lpage>483</lpage>.<pub-id pub-id-type="pmid">3195695</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Hotez</surname><given-names>PJ</given-names></name>, <name><surname>Molyneux</surname><given-names>DH</given-names></name>, <name><surname>Fenwick</surname><given-names>A</given-names></name>, <name><surname>Kumaresan</surname><given-names>J</given-names></name>, <name><surname>Sachs</surname><given-names>SE</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Control of neglected tropical diseases</article-title>. <source>N Engl J Med</source><volume>357</volume>: <fpage>1018</fpage>–<lpage>1027</lpage>.<pub-id pub-id-type="pmid">17804846</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>De Silva</surname><given-names>NR</given-names></name>, <name><surname>Guyatt</surname><given-names>HL</given-names></name>, <name><surname>Bundy</surname><given-names>DA</given-names></name> (<year>1997</year>) <article-title>Morbidity and mortality due to Ascaris-induced intestinal obstruction</article-title>. <source>Trans R Soc Trop Med Hyg</source><volume>91</volume>: <fpage>31</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">9093623</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Albonico</surname><given-names>M</given-names></name>, <name><surname>Allen</surname><given-names>H</given-names></name>, <name><surname>Chitsulo</surname><given-names>L</given-names></name>, <name><surname>Engels</surname><given-names>D</given-names></name>, <name><surname>Gabrielli</surname><given-names>A-F</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Controlling soil-transmitted helminthiasis in pre-school-age children through preventive chemotherapy</article-title>. <source>PLoS Negl Trop Dis</source><volume>2</volume>: <fpage>e126</fpage>.<pub-id pub-id-type="pmid">18365031</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Moncayo</surname><given-names>AL</given-names></name>, <name><surname>Vaca</surname><given-names>M</given-names></name>, <name><surname>Amorim</surname><given-names>L</given-names></name>, <name><surname>Rodriguez</surname><given-names>A</given-names></name>, <name><surname>Erazo</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Impact of Long-Term Treatment with Ivermectin on the Prevalence and Intensity of Soil-Transmitted Helminth Infections</article-title>. <source>PLoS Negl Trop Dis</source><volume>2</volume>: <fpage>e293</fpage>.<pub-id pub-id-type="pmid">18820741</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Whitworth</surname><given-names>JA</given-names></name>, <name><surname>Morgan</surname><given-names>D</given-names></name>, <name><surname>Maude</surname><given-names>GH</given-names></name>, <name><surname>McNicholas</surname><given-names>AM</given-names></name>, <name><surname>Taylor</surname><given-names>DW</given-names></name> (<year>1991</year>) <article-title>A field study of the effect of ivermectin on intestinal helminths in man</article-title>. <source>Trans R Soc Trop Med Hyg</source><volume>85</volume>: <fpage>232</fpage>–<lpage>234</lpage>.<pub-id pub-id-type="pmid">1909471</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Elkins</surname><given-names>DB</given-names></name>, <name><surname>Haswell-Elkins</surname><given-names>M</given-names></name>, <name><surname>Anderson</surname><given-names>RM</given-names></name> (<year>1988</year>) <article-title>The importance of host age and sex to patterns of reinfection with Ascaris lumbricoides following mass anthelmintic treatment in a South Indian fishing community</article-title>. <source>Parasitology</source><volume>96</volume> (<issue>Pt 1</issue>): <fpage>171</fpage>–<lpage>184</lpage>.<pub-id pub-id-type="pmid">3362574</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Xia</surname><given-names>ZH</given-names></name>, <name><surname>Su</surname><given-names>YL</given-names></name>, <name><surname>Yao</surname><given-names>SY</given-names></name>, <name><surname>Shen</surname><given-names>BR</given-names></name>, <name><surname>Wen</surname><given-names>LY</given-names></name>, <etal>et al</etal> (<year>1992</year>) [<article-title>Clinical observation on efficacy of ivermectin in the treatment of intestinal nematode infections</article-title>]. <source>Chin J Parasitol Parasit Dis</source><volume>10</volume>: <fpage>279</fpage>–<lpage>282</lpage>.</mixed-citation></ref><ref id="pntd.0004051.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Shikiya</surname><given-names>K</given-names></name>, <name><surname>Uehara</surname><given-names>T</given-names></name>, <name><surname>Uechi</surname><given-names>H</given-names></name>, <name><surname>Ohshiro</surname><given-names>J</given-names></name>, <name><surname>Arakaki</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>1991</year>) [<article-title>Clinical study on ivermectin against Strongyloides stercoralis</article-title>]. <source>J Japan Assoc Infect Dis</source><volume>65</volume>: <fpage>1085</fpage>–<lpage>1090</lpage>.</mixed-citation></ref><ref id="pntd.0004051.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Shikiya</surname><given-names>K</given-names></name>, <name><surname>Kinjo</surname><given-names>N</given-names></name>, <name><surname>Uehara</surname><given-names>T</given-names></name>, <name><surname>Uechi</surname><given-names>H</given-names></name>, <name><surname>Ohshiro</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>1992</year>) <article-title>Efficacy of ivermectin against Strongyloides stercoralis in humans</article-title>. <source>Intern Med</source><volume>31</volume>: <fpage>310</fpage>–<lpage>312</lpage>.<pub-id pub-id-type="pmid">1611180</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Datry</surname><given-names>A</given-names></name>, <name><surname>Hilmarsdottir</surname><given-names>I</given-names></name>, <name><surname>Mayorga-Sagastume</surname><given-names>R</given-names></name>, <name><surname>Lyagoubi</surname><given-names>M</given-names></name>, <name><surname>Gaxotte</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>1994</year>) <article-title>Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases</article-title>. <source>Trans R Soc Trop Med Hyg</source><volume>88</volume>: <fpage>344</fpage>–<lpage>345</lpage>.<pub-id pub-id-type="pmid">7974685</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Marti</surname><given-names>H</given-names></name>, <name><surname>Haji</surname><given-names>HJ</given-names></name>, <name><surname>Savioli</surname><given-names>L</given-names></name>, <name><surname>Chwaya</surname><given-names>HM</given-names></name>, <name><surname>Mgeni</surname><given-names>AF</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children</article-title>. <source>Am J Trop Med Hyg</source><volume>55</volume>: <fpage>477</fpage>–<lpage>481</lpage>.<pub-id pub-id-type="pmid">8940976</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Nontasut</surname><given-names>P</given-names></name>, <name><surname>Muennoo</surname><given-names>C</given-names></name>, <name><surname>Sa-nguankiat</surname><given-names>S</given-names></name>, <name><surname>Fongsri</surname><given-names>S</given-names></name>, <name><surname>Vichit</surname><given-names>A</given-names></name> (<year>2005</year>) <article-title>Prevalence of strongyloides in Northern Thailand and treatment with ivermectin vs albendazole</article-title>. <source>Southeast Asian J Trop Med Public Heal</source><volume>36</volume>: <fpage>442</fpage>–<lpage>444</lpage>.</mixed-citation></ref><ref id="pntd.0004051.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Olsen</surname><given-names>A</given-names></name>, <name><surname>van Lieshout</surname><given-names>L</given-names></name>, <name><surname>Marti</surname><given-names>H</given-names></name>, <name><surname>Polderman</surname><given-names>T</given-names></name>, <name><surname>Polman</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Strongyloidiasis—the most neglected of the neglected tropical diseases?</article-title><source>Trans R Soc Trop Med Hyg</source><volume>103</volume>: <fpage>967</fpage>–<lpage>972</lpage>.<pub-id pub-id-type="pmid">19328508</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Santiago</surname><given-names>M</given-names></name>, <name><surname>Leitão</surname><given-names>B</given-names></name> (<year>2009</year>) <article-title>Prevention of strongyloides hyperinfection syndrome: a rheumatological point of view</article-title>. <source>Eur J Intern Med</source><volume>20</volume>: <fpage>744</fpage>–<lpage>748</lpage>.<pub-id pub-id-type="pmid">19892301</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Stern</surname><given-names>MS</given-names></name>, <name><surname>Joshpe</surname><given-names>G</given-names></name> (<year>1971</year>) <article-title>Strongyloides stercoralis autoinfection</article-title>. <source>JAMA</source><volume>215</volume>: <fpage>297</fpage>–<lpage>298</lpage>.<pub-id pub-id-type="pmid">5107377</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Plaisier</surname><given-names>AP</given-names></name>, <name><surname>Cao</surname><given-names>WC</given-names></name>, <name><surname>van Oortmarssen</surname><given-names>GJ</given-names></name>, <name><surname>Habbema</surname><given-names>JD</given-names></name> (<year>1999</year>) <article-title>Efficacy of ivermectin in the treatment of Wuchereria bancrofti infection: a model-based analysis of trial results</article-title>. <source>Parasitology</source><volume>119</volume>: <fpage>385</fpage>–<lpage>394</lpage>.<pub-id pub-id-type="pmid">10581617</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Dunyo</surname><given-names>SK</given-names></name>, <name><surname>Nkrumah</surname><given-names>FK</given-names></name>, <name><surname>Simonsen</surname><given-names>PE</given-names></name> (<year>2000</year>) <article-title>A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana</article-title>. <source>Trans R Soc Trop Med Hyg</source><volume>94</volume>: <fpage>205</fpage>–<lpage>211</lpage>.<pub-id pub-id-type="pmid">10897370</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Taylor</surname><given-names>MJ</given-names></name>, <name><surname>Hoerauf</surname><given-names>A</given-names></name>, <name><surname>Bockarie</surname><given-names>M</given-names></name> (<year>2010</year>) <article-title>Lymphatic filariasis and onchocerciasis</article-title>. <source>Lancet</source><volume>376</volume>: <fpage>1175</fpage>–<lpage>1185</lpage>.<pub-id pub-id-type="pmid">20739055</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Richards</surname><given-names>FO</given-names></name>, <name><surname>Eigege</surname><given-names>A</given-names></name>, <name><surname>Pam</surname><given-names>D</given-names></name>, <name><surname>Kal</surname><given-names>A</given-names></name>, <name><surname>Lenhart</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Mass ivermectin treatment for onchocerciasis: lack of evidence for collateral impact on transmission of Wuchereria bancrofti in areas of co-endemicity</article-title>. <source>Filaria J</source><volume>4</volume>: <fpage>6</fpage>.<pub-id pub-id-type="pmid">16022728</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Kar</surname><given-names>SK</given-names></name>, <name><surname>Mania</surname><given-names>J</given-names></name>, <name><surname>Patnaik</surname><given-names>S</given-names></name> (<year>1994</year>) <article-title>The use of ivermectin for scabies</article-title>. <source>Natl Med J India</source><volume>7</volume>: <fpage>15</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">8156025</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Usha</surname><given-names>V</given-names></name>, <name><surname>Gopalakrishnan</surname><given-names>Nair T V</given-names></name> (<year>2000</year>) <article-title>A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies</article-title>. <source>J Am Acad Dermatol</source><volume>42</volume>: <fpage>236</fpage>–<lpage>240</lpage>.<pub-id pub-id-type="pmid">10642678</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Sule</surname><given-names>HM</given-names></name>, <name><surname>Thacher</surname><given-names>TD</given-names></name> (<year>2007</year>) <article-title>Comparison of ivermectin and benzyl benzoate lotion for scabies in Nigerian patients</article-title>. <source>Am J Trop Med Hyg</source><volume>76</volume>: <fpage>392</fpage>–<lpage>395</lpage>.<pub-id pub-id-type="pmid">17297053</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Meinking</surname><given-names>TL</given-names></name>, <name><surname>Taplin</surname><given-names>D</given-names></name>, <name><surname>Hermida</surname><given-names>JL</given-names></name>, <name><surname>Pardo</surname><given-names>R</given-names></name>, <name><surname>Kerdel</surname><given-names>FA</given-names></name> (<year>1995</year>) <article-title>The treatment of scabies with ivermectin</article-title>. <source>N Engl J Med</source><volume>333</volume>: <fpage>26</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">7776990</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Heukelbach</surname><given-names>J</given-names></name>, <name><surname>Winter</surname><given-names>B</given-names></name>, <name><surname>Wilcke</surname><given-names>T</given-names></name>, <name><surname>Muehlen</surname><given-names>M</given-names></name>, <name><surname>Albrecht</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Selective mass treatment with ivermectin to control intestinal helminthiases and parasitic skin diseases in a severely affected population</article-title>. <source>Bull World Heal Organ</source><volume>82</volume>: <fpage>563</fpage>–<lpage>571</lpage>.</mixed-citation></ref><ref id="pntd.0004051.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Abedin</surname><given-names>S</given-names></name>, <name><surname>Narang</surname><given-names>M</given-names></name>, <name><surname>Gandhi</surname><given-names>V</given-names></name>, <name><surname>Narang</surname><given-names>S</given-names></name> (<year>2007</year>) <article-title>Efficacy of permethrin cream and oral ivermectin in treatment of scabies</article-title>. <source>Indian J Pediatr</source><volume>74</volume>: <fpage>915</fpage>–<lpage>916</lpage>.<pub-id pub-id-type="pmid">17978449</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Badiaga</surname><given-names>S</given-names></name>, <name><surname>Foucault</surname><given-names>C</given-names></name>, <name><surname>Rogier</surname><given-names>C</given-names></name>, <name><surname>Doudier</surname><given-names>B</given-names></name>, <name><surname>Rovery</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>The effect of a single dose of oral ivermectin on pruritus in the homeless</article-title>. <source>J Antimicrob Chemother</source><volume>62</volume>: <fpage>404</fpage>–<lpage>409</lpage>.<pub-id pub-id-type="pmid">18456649</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Hengge</surname><given-names>UR</given-names></name>, <name><surname>Currie</surname><given-names>BJ</given-names></name>, <name><surname>Jäger</surname><given-names>G</given-names></name>, <name><surname>Lupi</surname><given-names>O</given-names></name>, <name><surname>Schwartz</surname><given-names>RA</given-names></name> (<year>2006</year>) <article-title>Scabies: a ubiquitous neglected skin disease</article-title>. <source>Lancet Infect Dis</source><volume>6</volume>: <fpage>769</fpage>–<lpage>779</lpage>.<pub-id pub-id-type="pmid">17123897</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Gilmore</surname><given-names>SJ</given-names></name> (<year>2011</year>) <article-title>Control strategies for endemic childhood scabies</article-title>. <source>PLoS One</source><volume>6</volume>: <fpage>e15990</fpage>.<pub-id pub-id-type="pmid">21283575</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Lawrence</surname><given-names>G</given-names></name>, <name><surname>Leafasia</surname><given-names>J</given-names></name>, <name><surname>Sheridan</surname><given-names>J</given-names></name>, <name><surname>Hills</surname><given-names>S</given-names></name>, <name><surname>Wate</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin</article-title>. <source>Bull World Heal Organ</source><volume>83</volume>: <fpage>34</fpage>–<lpage>42</lpage>.</mixed-citation></ref><ref id="pntd.0004051.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Feldmeier</surname><given-names>H</given-names></name> (<year>2009</year>) [<article-title>Tungiasis and cutaneous larva migrans: unpleasant travel souvenirs</article-title>]. <source>Med Monatsschr Pharm</source><volume>32</volume>: <fpage>440</fpage>–<lpage>444</lpage>.<pub-id pub-id-type="pmid">20088345</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Cestari</surname><given-names>TF</given-names></name>, <name><surname>Pessato</surname><given-names>S</given-names></name>, <name><surname>Ramos-e-Silva</surname><given-names>M</given-names></name><article-title>Tungiasis and myiasis</article-title>. <source>Clin Dermatol</source><volume>25</volume>: <fpage>158</fpage>–<lpage>164</lpage>.<pub-id pub-id-type="pmid">17350494</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Chaccour</surname><given-names>CJ</given-names></name>, <name><surname>Kobylinski</surname><given-names>KC</given-names></name>, <name><surname>Bassat</surname><given-names>Q</given-names></name>, <name><surname>Bousema</surname><given-names>T</given-names></name>, <name><surname>Drakeley</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination</article-title>. <source>Malar J</source><volume>12</volume>: <fpage>153</fpage>.<pub-id pub-id-type="pmid">23647969</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Boussinesq</surname><given-names>M</given-names></name>, <name><surname>Gardon</surname><given-names>J</given-names></name>, <name><surname>Gardon-Wendel</surname><given-names>N</given-names></name>, <name><surname>Chippaux</surname><given-names>J-P</given-names></name> (<year>2003</year>) <article-title>Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon</article-title>. <source>Filaria J</source><volume>2</volume><issue>Suppl 1</issue>: <fpage>S4</fpage>.<pub-id pub-id-type="pmid">14975061</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Boussinesq</surname><given-names>M</given-names></name>, <name><surname>Kamgno</surname><given-names>J</given-names></name>, <name><surname>Pion</surname><given-names>SD</given-names></name>, <name><surname>Gardon</surname><given-names>J</given-names></name> (<year>2006</year>) <article-title>What are the mechanisms associated with post-ivermectin serious adverse events?</article-title><source>Trends Parasitol</source><volume>22</volume>: <fpage>244</fpage>–<lpage>246</lpage>.<pub-id pub-id-type="pmid">16632406</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Zouré</surname><given-names>HGM</given-names></name>, <name><surname>Wanji</surname><given-names>S</given-names></name>, <name><surname>Noma</surname><given-names>M</given-names></name>, <name><surname>Amazigo</surname><given-names>UV</given-names></name>, <name><surname>Diggle</surname><given-names>PJ</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA)</article-title>. <source>PLoS Negl Trop Dis</source><volume>5</volume>: <fpage>e1210</fpage>.<pub-id pub-id-type="pmid">21738809</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Stolk</surname><given-names>WA</given-names></name>, <name><surname>de Vlas</surname><given-names>SJ</given-names></name>, <name><surname>Borsboom</surname><given-names>GJJM</given-names></name>, <name><surname>Habbema</surname><given-names>JDF</given-names></name> (<year>2008</year>) <article-title>LYMFASIM, a simulation model for predicting the impact of lymphatic filariasis control: quantification for African villages</article-title>. <source>Parasitology</source><volume>135</volume>: <fpage>1583</fpage>–<lpage>1598</lpage>.<pub-id pub-id-type="pmid">19006602</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref069"><label>69</label><mixed-citation publication-type="other">World Health Organization. PCT Databank. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/neglected_diseases/preventive_chemotherapy">www.who.int/neglected_diseases/preventive_chemotherapy</ext-link> (Accessed August 6, 2015).</mixed-citation></ref><ref id="pntd.0004051.ref070"><label>70</label><mixed-citation publication-type="other">World Health Organization (2006) Preventive chemotherapy in human helminthiasis. Geneva.</mixed-citation></ref><ref id="pntd.0004051.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Knopp</surname><given-names>S</given-names></name>, <name><surname>Mohammed</surname><given-names>K a</given-names></name>, <name><surname>Speich</surname><given-names>B</given-names></name>, <name><surname>Hattendorf</surname><given-names>J</given-names></name>, <name><surname>Khamis</surname><given-names>IS</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Albendazole and mebendazole administered alone or in combination with ivermectin against <italic>Trichuris trichiura</italic>: a randomized controlled trial</article-title>. <source>Clin Infect Dis</source><volume>51</volume>: <fpage>1420</fpage>–<lpage>1428</lpage>.<pub-id pub-id-type="pmid">21062129</pub-id></mixed-citation></ref><ref id="pntd.0004051.ref072"><label>72</label><mixed-citation publication-type="other">Uniting to Combat Neglected Tropical Diseases (2012) London Declaration on Neglected Tropical Diseases.</mixed-citation></ref><ref id="pntd.0004051.ref073"><label>73</label><mixed-citation publication-type="other">Uniting to Combat Neglected Tropical Diseases (2014) Delivering on Promises and Driving Progress.</mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000401 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000401 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |